60 Degrees Pharmaceuticals (SXTP) 10-Q 25 Aug 23 2023 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2023	Aug. 25, 2023
Document Information Line Items
Entity Registrant Name	60 DEGREES PHARMACEUTICALS, INC.
Document Type	10-Q
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		5,799,535
Amendment Flag	false
Entity Central Index Key	0001946563
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Document Period End Date	Jun. 30, 2023
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q2
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Shell Company	false
Entity Ex Transition Period	false
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	001-41719
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	45-2406880
Entity Address, Address Line One	1025 Connecticut Avenue
Entity Address, Address Line Two	NW Suite 1000
Entity Address, City or Town	Washington
Entity Address, State or Province	WA
Entity Address, Postal Zip Code	20036
City Area Code	(202)
Local Phone Number	327-5422
Entity Interactive Data Current	Yes
Common Stock, par value $0.0001 per share
Document Information Line Items
Trading Symbol	SXTP
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Security Exchange Name	NASDAQ
Warrants, each warrant to purchase one share of Common Stock
Document Information Line Items
Trading Symbol	SXTPW
Title of 12(b) Security	Warrants, each warrant to purchase one share of Common Stock
Security Exchange Name	NASDAQ

Consolidated Condensed Balance

Consolidated Condensed Balance Sheets - USD ($)	Jun. 30, 2023	Dec. 31, 2022
Current Assets:
Cash	$ 19,070	$ 264,865
Accounts Receivable	125,470	45,965
Prepaid and Other	4,849,473	200,967
Deferred Offering Costs	215,173	68,629
Inventory, net (Note 3)	465,515	518,578
Total Current Assets	5,674,701	1,099,004
Property and Equipment, net (Note 4)	7,498	21,300
Other Assets:
Right of Use Asset (Note 11)	39,070	12,647
Long-Term Prepaid Research	1,431,092
Intangible Assets, net (Note 5)	206,377	164,255
Total Other Assets	1,676,539	176,902
Total Assets	7,358,738	1,297,206
Current Liabilities:
Accounts Payable and Accrued Expenses	1,058,321	758,668
Lease Liability (Note 11)	39,470	13,000
Deferred Compensation (Note 7)	295,000	325,000
Related Party Notes, net (including accrued interest) (Note 8)	370,066	195,097
Debenture (Note 8)		4,276,609
SBA EIDL (including accrued interest) (Note 8)	8,772	2,750
Promissory Notes (including accrued interest), at fair value (Note 8)	23,539,996
Promissory Notes (including accrued interest) (Note 8)	1,105,122	16,855,887
Derivative Liabilities (Note 9)	2,084,916	1,129,840
Derivative Liabilities - Related Parties (Note 9)	361,175	364,360
Total Current Liabilities:	28,862,838	23,921,211
Long-Term Liabilities:
Deferred Compensation (Note 7)		255,000
SBA EIDL (including accrued interest) (Note 8)	152,594	160,272
Promissory Notes (including accrued interest) (Note 8)	1,220,155	1,109,783
Total Long-Term Liabilities	1,372,749	1,525,055
Total Liabilities	30,235,587	25,446,266
Commitments and Contingencies (Note 11)
SHAREHOLDERS’ DEFICIT:
Preferred stock, $0.0001 par value, 1,000,000 shares authorized, no shares issued and outstanding as of June 30, 2023 and December 31, 2022
Class A common stock, $0.0001 par value, 150,000,000 shares authorized; 2,378,009 and 2,386,009 shares issued and outstanding as of June 30, 2023 and December 31, 2022, respectively (Note 6)	238	239
Additional Paid-in Capital	12,379,462	5,164,461
Accumulated Other Comprehensive Income	72,044	73,708
Accumulated Deficit	(34,751,764)	(28,815,148)
60P Shareholders’ Deficit:	(22,300,020)	(23,576,740)
Noncontrolling interest	(576,829)	(572,320)
Total Shareholders' Deficit	(22,876,849)	(24,149,060)
Total Liabilities and Shareholders' Deficit	$ 7,358,738	$ 1,297,206

Consolidated Condensed Balanc_2

Consolidated Condensed Balance Sheets (Parentheticals) - $ / shares	Jun. 30, 2023	Dec. 31, 2022
Preferred stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, shares issued	2,378,009
Common stock, shares outstanding	2,378,009
Class A common stock [Member]
Common stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	2,378,009	2,386,009
Common stock, shares outstanding	2,378,009	2,386,009

Consolidated Condensed Statemen

Consolidated Condensed Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Income Statement [Abstract]
Product Revenues – net of Discounts and Rebates	$ 59,532	$ 45,173	$ 76,704	$ 92,197
Cost of Revenues	183,977	87,120	257,097	177,254
Gross Loss	(124,445)	(41,947)	(180,393)	(85,057)
Research Revenues	3,116	(7,740)	7,408	109,407
Net (Loss) Revenue	(121,329)	(49,687)	(172,985)	24,350
Operating Expenses:
Research and Development	203,872	231,394	327,866	294,451
General and Administrative Expenses	462,795	405,838	1,237,809	580,530
Total Operating Expenses	666,667	637,232	1,565,675	874,981
Loss from Operations	(787,996)	(686,919)	(1,738,660)	(850,631)
Interest Expense	(1,099,656)	(905,519)	(2,241,085)	(1,667,736)
Derivative Expense	(399,725)	(504,613)	(399,725)	(504,613)
Change in Fair Value of Derivative Liabilities	7,968	(1,001)	2,834	(1,001)
Loss on Debt Extinguishment			(839,887)
Change in Fair Value of Promissory Note	(1,064,849)		(725,797)
Other Income (Expense), net	730	(51,714)	1,321	(32,982)
Total Interest and Other Income (Expense), net	(2,555,532)	(1,462,847)	(4,202,339)	(2,206,332)
Loss from Operations before Provision for Income Taxes	(3,343,528)	(2,149,766)	(5,940,999)	(3,056,963)
Provision for Income Taxes (Note 10)	63	250	126	500
Net Loss including Noncontrolling Interest	(3,343,591)	(2,150,016)	(5,941,125)	(3,057,463)
Net Gain (Loss) – Noncontrolling Interest	(7,036)	(3,117)	(4,509)	1,718
Net Loss – attributed to 60 Degrees Pharmaceuticals, Inc.	(3,336,555)	(2,146,899)	(5,936,616)	(3,059,181)
Comprehensive Loss:
Net Loss	(3,343,591)	(2,150,016)	(5,941,125)	(3,057,463)
Unrealized Foreign Currency Translation Loss	(374)	(110,989)	(1,664)	(14,433)
Total Comprehensive Loss	(3,343,965)	(2,261,005)	(5,942,789)	(3,071,896)
Net Gain (Loss) – Noncontrolling Interest	(7,036)	(3,117)	(4,509)	1,718
Comprehensive Loss – attributed to 60 Degrees Pharmaceuticals, Inc.	$ (3,336,929)	$ (2,257,888)	$ (5,938,280)	$ (3,073,614)
Net Loss per common share:
Net Loss per common share Basic (in Dollars per share)	$ (1.4)	$ (0.96)	$ (2.54)	$ (1.31)
Weighted average number of common shares outstanding
Weighted average number of common shares outstanding Basic (in Shares)	2,378,009	2,349,349	2,341,274	2,349,147

Consolidated Condensed Statem_2

Consolidated Condensed Statements of Operations and Comprehensive Loss (Unaudited) (Parentheticals) - $ / shares	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Income Statement [Abstract]
Net Loss per common share Diluted	$ (1.40)	$ (0.96)	$ (2.54)	$ (1.31)
Weighted average number of common shares outstanding Diluted	2,378,009	2,349,349	2,341,274	2,349,147

Consolidated Condensed Statem_3

Consolidated Condensed Statements of Shareholders’ and Members’ Deficit (Unaudited) - USD ($)	Members’ Equity	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Accumulated Other Comprehensive Income (Loss)	Total Shareholders’ Equity (Deficit) Attributable to 60P	Noncontrolling Interest on Shareholders	Total
Balance at Dec. 31, 2021	$ 4,979,365			$ (22,633,428)	$ 75,835	$ (17,578,228)	$ (576,256)	$ (18,154,484)
Balance (in Shares) at Dec. 31, 2021	18,855,165
Net Foreign Translation Gain (Loss)					96,556	96,556		96,556
Net Gain (Loss)				(912,282)		(912,282)	4,835	(907,447)
Balance at Mar. 31, 2022	$ 4,979,365			(23,545,710)	172,391	(18,393,954)	(571,421)	(18,965,375)
Balance (in Shares) at Mar. 31, 2022	18,855,165
Balance at Dec. 31, 2021	$ 4,979,365			(22,633,428)	75,835	(17,578,228)	(576,256)	(18,154,484)
Balance (in Shares) at Dec. 31, 2021	18,855,165
Net Gain (Loss)								(3,057,463)
Balance at Jun. 30, 2022		$ 239	5,164,461	(25,692,609)	61,402	(20,466,507)	(574,538)	(21,041,045)
Balance (in Shares) at Jun. 30, 2022		2,386,009
Balance at Mar. 31, 2022	$ 4,979,365			(23,545,710)	172,391	(18,393,954)	(571,421)	(18,965,375)
Balance (in Shares) at Mar. 31, 2022	18,855,165
Business Combination: June 1, 2022 (60P LLC into 60P, Inc.)	$ (4,979,365)	$ 235	4,979,130
Business Combination: June 1, 2022 (60P LLC into 60P, Inc.) (in Shares)	(18,855,165)	2,348,942
Issuance of Common Stock		$ 4	185,331			185,335		185,335
Issuance of Common Stock (in Shares)		37,067
Net Foreign Translation Gain (Loss)					(110,989)	(110,989)		(110,989)
Net Gain (Loss)				(2,146,899)		(2,146,899)	(3,117)	(2,150,016)
Balance at Jun. 30, 2022		$ 239	5,164,461	(25,692,609)	61,402	(20,466,507)	(574,538)	(21,041,045)
Balance (in Shares) at Jun. 30, 2022		2,386,009
Balance at Dec. 31, 2022		$ 239	5,164,461	(28,815,148)	73,708	(23,576,740)	(572,320)	(24,149,060)
Balance (in Shares) at Dec. 31, 2022		2,386,009
Issuance of Common Stock		$ 144	7,214,856			7,215,000		7,215,000
Issuance of Common Stock (in Shares)		1,443,000
Cancellation of common stock		$ (145)	145
Cancellation of common stock (in Shares)		(1,451,000)
Net Foreign Translation Gain (Loss)					(1,290)	(1,290)		(1,290)
Net Gain (Loss)				(2,600,061)		(2,600,061)	2,527	(2,597,534)
Balance at Mar. 31, 2023		$ 238	12,379,462	(31,415,209)	72,418	(18,963,091)	(569,793)	(19,532,884)
Balance (in Shares) at Mar. 31, 2023		2,378,009
Balance at Dec. 31, 2022		$ 239	5,164,461	(28,815,148)	73,708	(23,576,740)	(572,320)	(24,149,060)
Balance (in Shares) at Dec. 31, 2022		2,386,009
Net Gain (Loss)								(5,941,125)
Balance at Jun. 30, 2023		$ 238	12,379,462	(34,751,764)	72,044	(22,300,020)	(576,829)	(22,876,849)
Balance (in Shares) at Jun. 30, 2023		2,378,009
Balance at Mar. 31, 2023		$ 238	12,379,462	(31,415,209)	72,418	(18,963,091)	(569,793)	(19,532,884)
Balance (in Shares) at Mar. 31, 2023		2,378,009
Net Foreign Translation Gain (Loss)					(374)	(374)		(374)
Net Gain (Loss)				(3,336,555)		(3,336,555)	(7,036)	(3,343,591)
Balance at Jun. 30, 2023		$ 238	$ 12,379,462	$ (34,751,764)	$ 72,044	$ (22,300,020)	$ (576,829)	$ (22,876,849)
Balance (in Shares) at Jun. 30, 2023		2,378,009

Consolidated Condensed Statem_4

Consolidated Condensed Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
CASH FLOWS FROM OPERATING ACTIVITIES
Net Loss	$ (5,941,125)	$ (3,057,463)
Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities:
Depreciation	13,802	13,846
Amortization	13,192	1,962
Amortization of Debt Discount	645,336	326,396
Amortization of ROU Asset	24,500	22,135
Amortization of Note Issuance Costs	64,239	12,144
Amortization of Capitalized Services	534,408
Stock-based Compensation	277,605
Loss on Debt Extinguishment	839,887
Change in Fair Value of Derivative Liabilities	(2,834)	1,001
Derivative Expense	399,725	504,613
Change in Fair Value of Promissory Note	725,797
Inventory Reserve	52,301	76,644
Changes in Operating Assets and Liabilities:
Accounts Receivable	(79,505)	96,030
Prepaid and Other	(35,507)	116,115
Inventory	762	(56,986)
Accounts Payable and Accrued Liabilities	299,653	(25,840)
Accrued Interest	1,426,049	1,198,896
Reduction of Lease Liability	(24,453)	(22,205)
Deferred Compensation	40,000	155,768
Net Cash Used in Operating Activities	(726,168)	(636,944)
CASH FLOWS FROM INVESTING ACTIVITIES
Capitalization of Patents	(15,419)	(2,907)
Acquisition of Intangibles	(6,000)
Net Cash Used in Investing Activities	(21,419)	(2,907)
CASH FLOWS FROM FINANCING ACTIVITIES
Payment of Deferred Offering Costs	(146,544)
Issuance of Common Stock		185,335
Proceeds from Notes Payable	650,000	800,000
Proceeds from Notes Payable - Related Parties		305,000
Advances from Related Parties	250,000
Repayment of Related Party Advances	(250,000)
Net Cash Provided by Financing Activities	503,456	1,290,335
Foreign Currency Translation Loss	(1,664)	(14,433)
Change in Cash	(245,795)	636,051
Cash—Beginning of Period	264,865	115,399
Cash—End of Period	19,070	751,450
NONCASH INVESTING/FINANCING ACTIVITIES
Common Stock Issued as Prepayment for Services	7,215,000
Additions to ROU Assets for Lease Renewal	50,922
Additions to Lease Liabilities for Lease Renewal	50,570
Conversion of 60P LLC Member Units to Common Stock		4,979,365
Debt Discount Recorded in Connection with Derivative Liabilities	$ 650,000	$ 1,105,000

Nature of Operations

Nature of Operations	6 Months Ended
	Jun. 30, 2023
Nature of Operations [Abstract]
NATURE OF OPERATIONS	1. NATURE OF OPERATIONS 60 Degrees Pharmaceuticals, Inc. was incorporated in Delaware on June 1, 2022 and merged on the same day with 60 Degrees Pharmaceuticals, LLC, a District of Columbia limited liability company organized on September 9, 2010 (“60P LLC”). 60 Degrees Pharmaceuticals, Inc. and its subsidiaries (referred to collectively as the “Company”, “60P”, or “60 Degrees Pharmaceuticals”) is a specialty pharmaceutical company that specializes in the development and marketing of new medicines for the treatment and prevention of infectious diseases. 60P achieved FDA approval of its lead product, ARAKODA® (tafenoquine), for malaria prevention, in 2018. Currently, 60P’s pipeline under development covers development programs for COVID-19, fungal, tick-borne, and other viral diseases utilizing three of the Company’s future products: (i) new products that contain the Arakoda regimen of tafenoquine; (ii) new products that contain tafenoquine; and (iii) celgosivir. The Company’s headquarters are located in Washington, D.C., with a majority-owned subsidiary in Australia. Initial Public Offering On July 14, 2023, the Company closed its initial public offering consisting of 1,415,095 units at a price of $5.30 per unit for approximately $6,454,300 in net proceeds, after deducting the underwriting discount and commission and other estimated offering expenses payable by the Company. Each unit consisted of one share of common stock of the Company, par value $0.0001 per share, one tradeable warrant to purchase one share of common stock at an exercise price of $6.095 per share, and one non-tradeable warrant to purchase one share of the Company’s common stock at an exercise price of $6.36 per share (the “IPO”). The units were offered and sold pursuant to the Company’s Registration Statement on Form S-1, as amended (File No. 333-269483), originally filed with the Securities and Exchange Commission (the “SEC”) on January 31, 2023 (the “Registration Statement”) and the final prospectus filed with the Commission pursuant to Rule 424(b)(4) of the Securities Act of 1933, as amended. The Registration Statement was declared effective by the Commission on July 11, 2023. The common stock and tradeable warrants began trading on The Nasdaq Capital Market on July 12, 2023 under the symbols “SXTP” and “SXTPW,” respectively. The closing of the IPO occurred on July 14, 2023. As of the completion of the IPO, among other things, certain of the Company’s then-outstanding convertible debt were converted into shares of common stock. See Notes 9 and 12 for more information. Going Concern The Company’s financial statements are prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of obligations in the normal course of business. However, the Company has not demonstrated the ability to generate enough revenues to date to cover operating expenses and has accumulated losses to date. This condition, among others, raises substantial doubt about the ability of the Company to continue as a going concern for one year from the date these financial statements are issued. In view of these matters, continuation as a going concern is dependent upon continued operations of the Company, which in turn is dependent upon the Company’s ability to meet its financial requirements, raise additional capital, and the success of its future operations. The financial statements do not include any adjustments to the amount and classification of assets and liabilities that may be necessary should the Company not continue as a going concern. Management plans to fund operations of the Company through third party and related party debt/advances, private placement of restricted securities and the issuance of stock in a public offering until such a time as a business combination or other profitable investment may be achieved.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2023
Summary of Significant Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The financial statements of 60P and its subsidiaries are prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). The Company has prepared the accompanying consolidated condensed financial statements pursuant to the instructions to Form 10-Q and Article 8 of Regulation S-X of the Securities and Exchange Commission (“SEC”). These financial statements are unaudited and, in our opinion, include all adjustments consisting of normal recurring adjustments and accruals necessary for a fair presentation of our consolidated condensed balance sheets, consolidated condensed statements of operations and other comprehensive loss, consolidated condensed statements of shareholders’ and member’s deficit and consolidated condensed statements of cash flows for the periods presented. Operating results for the periods presented are not necessarily indicative of the results that may be expected for the year ending December 31, 2023 due to various factors. Certain information and footnote disclosures normally included in complete financial statements prepared in accordance with U.S. GAAP have been omitted in accordance with the rules and regulations of the SEC. These consolidated condensed financial statements should be read in conjunction with the audited consolidated financial statements and related notes thereto as contained in the Company’s Registration Statement. Principles of Consolidation and Noncontrolling Interest The Company’s consolidated condensed financial statements include the financial statements of its majority owned (87.53%) subsidiary 60P Australia Pty Ltd, as well as the financial statements of 60P Singapore Pty Lte, a wholly owned subsidiary of 60P Australia Pty Ltd. All significant intercompany accounts and transactions have been eliminated in consolidation. 60P Singapore Pty Lte was closed via dissolution as of March 31, 2022. 60P Singapore Pty Lte was originally set up to conduct research in Singapore. The entity had no assets and its liabilities were to both 60P Australia Pty Ltd, its direct owner, and 60P. Through consolidation accounting the closure of the business unit resulted in a currency exchange gain. For entities that are consolidated, but not 100% owned, a portion of the income or loss and corresponding equity is allocated to owners other than the Company. The aggregate of the income or loss and corresponding equity that is not owned by us is included in Noncontrolling Interest in the consolidated financial statements. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates, and those estimates may be material. Significant estimates include the reserve for inventory, deferred compensation, derivative liabilities, certain promissory notes carried at fair value, and valuation allowance for the deferred tax asset. Cash and Cash Equivalents Cash and cash equivalents include all cash in banks and short-term highly liquid investments (with original maturities of three months or less) as cash equivalents. The Company’s cash is deposited in demand accounts at financial institutions that management believes are creditworthy. The Company’s cash and cash equivalents in bank deposit accounts, at times, may exceed federally insured limits. On June 30, 2023, the Company’s cash and cash equivalents did not exceed FDIC insured limits (did not exceed FDIC insured limits at December 31, 2022). The Company also held cash at its subsidiary in Australia though the amounts were minimal. The Company has not experienced any losses related to amounts in excess of FDIC limits. The Company does not hold any cash equivalents, which would consist of highly liquid investments with original maturities of three months or less at the time of purchase. Accounts Receivable and Allowance for Doubtful Accounts The Company records accounts receivable at net realizable value. This value includes an appropriate allowance for estimated uncollectible accounts to reflect any loss anticipated on the trade accounts receivable balances and charged to the provision for doubtful accounts. Based on the Company’s history there has been no need to make a recording to Allowance for Doubtful Accounts. Most of the Company’s revenue has been earned via government contracts, and with a large American pharmaceutical distributor. As the Company continues to engage with smaller distributors, we will continue to analyze whether an allowance should be established. There was no allowance as of June 30, 2023 and December 31, 2022. At June 30, 2023, the US government accounted for 24% of the outstanding Accounts Receivable balance (66% at December 31, 2022) and the American pharmaceutical distributor accounted for 76% of the outstanding Accounts Receivable balance (30% for the year ended December 31, 2022). Inventory Inventories are stated at the lower of cost or net realizable value. Cost is comprised of direct materials and, where applicable, costs that have been incurred in bringing the inventories to their present location and condition. The Company uses the Specific Identification method per lot. A box price is calculated per lot number and sales are recognized by their lot number. Property and Equipment Property and equipment are stated at cost. Normal repairs and maintenance costs are charged to earnings as incurred and additions and major improvements are capitalized. The cost of assets retired or otherwise disposed of and the related depreciation are eliminated from the accounts in the period of disposal and the resulting gain or loss is credited or charged to earnings. Depreciation is computed over the estimated useful lives of the related asset type or term of the operating lease using the straight-line method for financial statement purposes. The estimated service lives for Property and Equipment is either three (3), five (5) or seven (7) years. Impairment of Long-lived Assets Long-lived assets, such as property and equipment and identifiable intangibles with finite useful lives, are periodically evaluated for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. We look for indicators of a trigger event for asset impairment and pay attention to any adverse change in the extent or manner in which the asset is being used or in its physical condition. Assets are grouped and evaluated for impairment at the lowest level of which there are identifiable cash flows, which is generally at a location level. Assets are reviewed using factors including, but not limited to, our future operating plans and projected cash flows. The determination of whether impairment has occurred is based on an estimate of undiscounted future cash flows directly related to the assets, compared to the carrying value of the assets. If the sum of the undiscounted future cash flows of the assets does not exceed the carrying value of the assets, full or partial impairment may exist. If the asset’s carrying amount exceeds its fair value, an impairment charge is recognized in the amount by which the carrying amount exceeds the fair value of the asset. Fair value is determined using an income approach, which requires discounting the estimated future cash flows associated with the asset. Intangible Assets The Company capitalizes its patent and filing fees and legal patent and prosecution fees in connection with internally developed pending patents. When pending patents are issued, patents will be amortized over the expected period to be benefitted, not to exceed the patent lives, which may be as long as ten to fifteen years. Website Development Costs The Company accounts for website development costs in accordance with ASC 350-50 “Website Development Costs”. Accordingly, all costs incurred in the planning stage are expensed as incurred, costs incurred in the website application and infrastructure development stage that meet specific criteria are capitalized and costs incurred in the day-to-day operation of the website are expensed as incurred. All costs associated with the websites are subject to straight-line amortization over a three-year period. During the three and also for the six months ended June 30, 2023, the Company capitalized website development or related costs of $6,000 and $39,895, respectively, in connection with the upgrade and enhancement of functionality of the corporate website at www.60-p.com ($0 and $0 for the three and six months ended June 30, 2022, respectively). Derivative Liabilities The Company assessed the classification of its derivative financial instruments as of June 30, 2023 and December 31, 2022, which consist of bridge shares, convertible notes payable and certain warrants (excluding those for compensation) and has determined that such instruments qualify for treatment as derivative liabilities as they meet the criteria for liability classification under ASC 815. The Company analyzes all financial instruments with features of both liabilities and equity under the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic No. 480, (“ASC 480”), Distinguishing Liabilities from Equity and FASB ASC Topic No. 815, Derivatives and Hedging (“ASC 815”). Derivative liabilities are adjusted to reflect fair value at each reporting period, with any increase or decrease in the fair value recorded in the results of operations (other income/expense) as change in fair value of derivative liabilities. The Company uses a Monte Carlo Simulation Model to determine the fair value of these instruments. Upon conversion or repayment of a debt or equity instrument in exchange for shares of common stock, where the embedded conversion option has been bifurcated and accounted for as a derivative liability (generally convertible debt and warrants), the Company records the shares of common stock at par value, relieves all related debt, derivative liabilities, and debt discounts, and recognizes a net gain or loss on debt extinguishment. In connection with the debt extinguishment, the Company typically records an increase to additional paid-in capital for any remaining liability balance. Equity instruments that are initially classified as equity that become subject to reclassification under ASC Topic 815 are reclassified to liabilities at the fair value of the instrument on the reclassification date. Original Issue Discount (“OID”) For certain notes issued, the Company may provide the debt holder with an original issue discount. The original issue discount is recorded as a debt discount and is amortized to interest expense using the effective interest method over the life of the debt in the Consolidated Statements of Operations and Comprehensive Loss. Debt Issuance Costs Debt issuance costs paid to lenders, or third parties are recorded as debt discounts and amortized to interest expense over the life of the underlying debt instrument, in the Consolidated Statements of Operations and Comprehensive Loss, with the exception of certain debt for which we elected the fair value option. Debt issuance costs associated with debt for which the fair value option is elected are expensed as incurred. Income Taxes 60 Degrees Pharmaceuticals, Inc. is a corporation and has accepted the default taxation status of C corporation. The Merger in 2022 (See Note 6) did not materially impact tax matters as 60P LLC had elected to be taxed as a C corporation for income tax purposes at the beginning of 2022. The District of Columbia (“DC”) taxes corporations on form D-20 (DC Corporation Franchise Tax Return) and returns have a minimum tax due of $250 if gross receipts are at $1 million or less and a $1,000 if above. The tax years that remain subject to examination by major tax jurisdictions include the years ended December 31, 2019, 2020, 2021 and 2022. 60P Australia Pty Ltd. is subject to the taxes of the Australian Taxation Office and 60P Singapore Pte Ltd. was subject to the taxes of the Inland Revenue Authority of Singapore prior to its dissolution as of March 31, 2022. Management assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to use the existing deferred tax assets. On the basis of this evaluation, the Company has determined that it is more likely than not that the Company will not recognize the benefits of the foreign and state net deferred tax assets, and, as a result, full valuation allowance has been set against its net deferred tax assets as of June 30, 2023 and December 31, 2022. The Company recognizes the impact of a tax position in the financial statements if that position is more likely than not to be sustained on a tax return upon examination by the relevant taxing authority, based on the technical merits of the position. As of June 30, 2023, and December 31, 2022, the Company had no recognized tax benefits. The Company recognizes interest and penalties related to income tax matters as other expense and non-deductible penalties, respectively. As of June 30, 2023, the Company has recognized a potential tax penalty regarding a US foreign tax reporting form of $30,000 ($30,000 at December 31, 2022). Concentrations Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash, accounts receivable, inventory purchases, and lending. Significant customers represent any customer whose business makes up 10% of our receivables or revenues. 100% of receivables as of June 30, 2023 (consisting of two significant customers at 76% and 24%) and 100% of total net revenues for the three months ended June 30, 2023 were generated by one significant customer (100% for the three months ended June 30, 2022 consisting of one significant customer). At December 31, 2022, 98% of the Company’s receivables, consisting of three customers and two significant at 59% and 39%, were generated from significant customers. 100% of the revenues were generated by the Company from one significant customer during the six months ended June 30, 2023 (100% for the six months ended June 30, 2022 consisting of one significant customer). Currently, the Company has exclusive relationships with distributors in Australia and Europe. A failure to perform by any of our current distributors would create disruption for patients in those markets. The US government has historically been the Company’s largest customer through a purchase support contract and a clinical study. Both of those activities ended during 2022 and near-term receivables and revenues from the government are not anticipated to be significant. Since the Company first started working on tafenoquine all inventory has been acquired in a collaborative relationship from a sole vendor. Should the vendor cease to supply tafenoquine it would take significant costs and efforts to rebuild the supply chain with a new sole vendor sourcing the active pharmaceutical ingredient (“API”). As of June 30, 2023, 84% (85% at December 31, 2022) of the Company’s non-related party debt is held by Knight Therapeutics, the senior secured lender and also a publicly traded Canadian company. The amount of senior secured debt with Knight Therapeutics currently limits the Company’s ability to access additional credit and management has been informed that additional lending with Knight Therapeutics is not currently possible. Business Segments The Company uses the “management approach” to identify its reportable segments. The management approach requires companies to report segment financial information consistent with information used by management for making operating decisions and assessing performance as the basis for identifying the Company’s reportable segments. To date, the Company has managed its business in one identifiable segment. Revenue Recognition The Company recognizes revenue in accordance with FASB ASC Topic No. 606, Revenue from Contracts with Customers (“ASC 606”). Revenues are recognized when control is transferred to customers in amounts that reflect the consideration the Company expects to be entitled to receive in exchange for those goods. Revenue recognition is evaluated through the following five steps: (i) identification of the contract, or contracts, with a customer; (ii) identification of the performance obligations in the contract; (iii) determination of the transaction price; (iv) allocation of the transaction price to the performance obligations in the contract; and (v) recognition of revenue when or as a performance obligation is satisfied. The Company receives the majority of its revenues from sales of its Arakoda™ product to resellers in the US and abroad. The Company records US commercial revenues as a receivable when our American distributor transfers shipped product to their title model for 60P. Foreign sales to both Australia and Europe are recognized as a receivable at the point product is shipped to distributor. The shipments to Australia and Europe are further subject to profit sharing agreements for boxes sold to customers. Research and Development Costs The Company accounts for research and development costs in accordance with FASB ASC Subtopic No. 730-10, Research and Development (“ASC 730-10”). Under ASC 730-10, research and development costs are expensed as incurred. Accordingly, internal research and development costs are expensed as incurred. Prepaid research and development costs are deferred and amortized over the service period as the services are provided. The Company recorded $203,872 and $327,866 in research and development costs expense during the three and six months ended June 30, 2023, respectively ($231,394 and $294,451 for the three and six months ended June 30, 2022, respectively). During the three and six months ended June 30, 2023, the Company deferred prepaid research and development costs in exchange for share-based payments of 525,000 common stock shares and 405,000 common stock shares to two nonemployees, Kentucky Technology Inc. and Florida State University Research Fund, Inc., respectively. The agreements with these nonemployees do not include any provisions to claw back the share-based payments in the event of nonperformance by the nonemployees. Subject to applicable federal and state security laws, the nonemployees can sell the received equity instruments. Kentucky Technology Inc. is expected to render research and development services to identify a combination drug partner for tafenoquine over a period of one year. Florida State University Research Fund, Inc. is expected to render research and development services related to development of celgosivir over a period of up to five years. At June 30, 2023, the Company recorded $3,130,000 current unamortized deferred prepaid research and development costs ($0 at December 31, 2022) and $1,431,092 non-current unamortized deferred prepaid research and development costs ($0 at December 31, 2022). Current unamortized deferred prepaid research and development costs are presented as a component of Prepaid and Other on the accompanying consolidated condensed balance sheets. Fair Value of Financial Instruments and the Fair Value Option (“FVO”) The carrying value of the Company’s financial instruments included in current assets and current liabilities (such as cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses) approximate their fair value due to the short-term nature of such instruments. The inputs used to measure fair value are based on a hierarchy that prioritizes observable and unobservable inputs used in valuation techniques. These levels, in order of highest to lowest priority, are described below: Level 1 — Quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets or liabilities. Level 2 — Observable prices that are based on inputs not quoted on active markets but corroborated by market data. Level 3 — Unobservable inputs reflecting the Company’s assumptions, consistent with reasonably available assumptions made by other market participants. These valuations require significant judgment. The Company may choose to elect the FVO for certain eligible financial instruments, such as Promissory Notes, in order to simplify the accounting treatment. Items for which the FVO has been elected are presented at fair value in the consolidated balance sheets and any change in fair value unrelated to credit risk is recorded in other income in the consolidated statements of operations. Changes in fair value related to credit risk are recognized in other comprehensive income. The Company’s financial instruments recorded at fair value on a recurring basis at June 30, 2023, and December 31, 2022 include the certain convertible promissory notes for which the Company elected the FVO and Derivative Liabilities, which are carried at fair value based on Level 3 inputs. See Notes 8 and 9 regarding Promissory Notes, at fair value and Derivative Liabilities, respectively. Liabilities measured at fair value at June 30, 2023 and December 31, 2022 are as follows: June 30, 2023 Level 1 Level 2 Level 3 Total Liabilities: Promissory Notes (including accrued interest), at fair value $ - $ - $ 23,539,996 $ 23,539,996 Derivative Liabilities - - 2,446,091 2,446,091 Total $ - $ - $ 25,986,087 $ 25,986,087 December 31, 2022 Level 1 Level 2 Level 3 Total Liabilities: Derivative Liabilities $ - $ - $ 1,494,200 $ 1,494,200 Total $ - $ - $ 1,494,200 $ 1,494,200 Foreign Currency Transactions and Translation The individual financial statements of each group entity are measured and presented in the currency of the primary economic environment in which the entity operates (its functional currency). The consolidated financial statements of the group and the statement of financial position and equity of the company are presented in US dollars, which is the functional currency of the Company and the presentation currency for the consolidated financial statements. For the purpose of presenting consolidated financial statements, the assets and liabilities of the group’s foreign operations are mostly translated at exchange rates prevailing on the reporting date. Income and expense items are translated at the average exchange rates for the period, unless exchange rates fluctuate significantly during that period, in which case the exchange rates at the dates of the transactions are used. Exchange differences arising, if any, are recognized in other income. Exchange rates along with historical rates used in these financial statements are as follows: Average Exchange Rate Three Months Ended June 30, Six Months Ended June 30, As of Currency 2023 2022 2023 2022 June 30, December 31, 1 AUD = 0.6683 USD 0.7147 USD 0.6761 USD 0.7194 USD 0.6662 USD 0.6805 USD 1 SGD = NA 0.9950 AUD* NA 1.0150 AUD* NA 1.0230 AUD* * Through 4/30/2022 (account closure date) Reclassifications Certain prior period amounts have been reclassified for consistency with the current period presentation. These reclassifications had no material effect on the consolidated results of operations and comprehensive loss, shareholders’ and members’ deficit, or cash flows. Accumulated Comprehensive Income (Loss) Other comprehensive loss consists of foreign currency translation adjustments and unrealized gains and losses from cash flow hedges. 2022 Equity Incentive Plan On November 22, 2022, the Company adopted the 2022 Equity Incentive Plan also referred to as (“2022 Plan”). As of June 30, 2023, the maximum shares available under the 2022 Plan is equal to 238,601. Share-Based Payments The Company measures compensation for all share-based payment awards granted to employees, directors, and nonemployees, based on the estimated fair value of the awards on the date of grant. For awards that vest based on continued service, the service-based compensation cost is recognized on a straight-line basis over the requisite service period, which is generally the vesting period of the awards. For service vesting awards with compensation expense recognized on a straight-line basis, at no point in time does the cumulative grant date value of vested awards exceed the cumulative amount of compensation expense recognized. The Company accounts for forfeitures as they occur. For awards that vest upon a liquidity event or a change in control, the performance condition is not probable of being achieved until the event occurs. As a result, no compensation expense is recognized until the performance-based vesting condition is achieved, at which time the cumulative compensation expense will be recognized. For fully vested, nonforfeitable equity instruments that are granted at the date the Company and a nonemployee enter into an agreement for goods or services, the Company recognizes the equity instruments when they are granted. The corresponding cost is recognized as an immediate expense or a prepaid asset depending on the specific facts and circumstances of the agreement with the nonemployee. During the six months ended June 30, 2023 and 2022, 513,000 and 0 common stock shares, respectively, were issued as fully vested, nonforfeitable equity instruments to nonemployees. The agreements with the nonemployees do not include any provisions to claw back the share-based payments in the event of nonperformance by the nonemployees. Subject to applicable federal and state securities laws, the nonemployees can sell the received equity instruments. 120,000 and 100,000 of the common stock shares issued during the six months ended June 30, 2023 were issued to Trevally, LLC and Carmel, Milazzo & Feil LLP, respectively. Before March 31, 2024, Trevally, LLC is expected to provide castanopsermine, a stable starting material to support the manufacture of good manufacturing grade (GMP)-grade celgosivir for clinical studies. Carmel, Milazzo & Feil LLP is expected to provide legal services before March 31, 2024. As of June 30, 2023, the unamortized balance of prepaid assets related to these share-based payments for which the services are expected to be rendered within one year is $1,100,000 ($0 at December 31, 2022), which is reported in Prepaid and Other on the Consolidated Condensed Balance Sheets. Net Loss per Common Share Net Loss per Common Share is computed by dividing net loss by the weighted average number of common shares outstanding during each period. For the purposes of calculating the weighted average number of common shares outstanding for periods prior to the Merger (See Note 6), each of 60P LLC’s outstanding membership units as of June 1, 2022 have been retrospectively adjusted for the equivalent number of common shares issued pursuant to the Merger. As the Company has reported a net loss for all periods presented, diluted net loss per common share is the same as basic net loss per common share for those periods. Related Parties Parties are considered to be related to the Company if the parties, directly or indirectly, through one or more intermediaries, control, are controlled by, or are under common control with the Company. Related parties also include principal owners of the Company, its management, members of the immediate families of principal owners of the Company and its management and other parties with which the Company may deal with if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests. Subsequent Events The Company considers events or transactions that occur after the balance sheet date, but prior to the issuance of the financial statements to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. Subsequent events have been evaluated through August 25, 2023, which is the date the financial statements were issued. See Note 12. Recently Issued and Adopted Accounting Pronouncements From time to time, the FASB issues Accounting Standards Updates (“ASU”) to amend the authoritative literature in the ASC. Management believes that those issued to date either (i) provide supplemental guidance, (ii) are technical corrections, (iii) are not applicable to the Company or (iv) are not expected to have a significant impact on these consolidated condensed financial statements. In August 2020, the FASB issued ASU 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”), as part of its overall simplification initiative to reduce costs and complexity of applying accounting standards while maintaining or improving the usefulness of the information provided to users of financial statements. Among other changes, the new guidance removes from U.S. GAAP separation models for convertible debt that require the convertible debt to be separated into a debt and equity component, unless the conversion feature is required to be bifurcated and accounted for as a derivative or the debt is issued at a substantial premium. As a result, after adopting the guidance, entities will no longer separately present such embedded conversion features in equity and will instead account for the convertible debt wholly as debt. The new guidance also requires use of the “if-converted” method when calculating the dilutive impact of convertible debt on earnings per share, which is consistent with the Company’s current accounting treatment under the current guidance. The guidance is effective for financial statements issued for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years, with early adoption permitted, but only at the beginning of the fiscal year. The Company adopted this pronouncement on January 1, 2022; however, the adoption of this standard did not have a material effect on the Company’s consolidated condensed financial statements. In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options. This latter standard provides clarification and reduces diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (such as warrants) that remain equity classified after modification or exchange. This standard is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Issuers should apply the new standard prospectively to modifications or exchanges occurring after the effective date of the new standard. Early adoption is permitted, including adoption in an interim period. If an issuer elects to early adopt the new standard in an interim period, the guidance should be applied as of the beginning of the fiscal year that includes that interim period. The Company’s adoption of this standard in 2022 did not have a material effect on the Company’s consolidated condensed financial statement. In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers, which requires an acquirer in a business combination to recognize and measure contract assets and contract liabilities in accordance with Accounting Standards Codification Topic 606. ASU 2021-08 is effective for fiscal years beginning after December 15, 2022 and early adoption is permitted. The Company’s adoption of ASU 2021-08 did not have an effect on its consolidated condensed financial statements.

Inventory

Inventory	6 Months Ended
	Jun. 30, 2023
Inventory [Abstract]
INVENTORY	3. INVENTORY Inventory consists of the following major classes: June 30, December 31, Raw Material (API) $ 397,487 $ 397,487 Packaging - 97,486 Finished Goods 301,112 183,943 Clinical Trial Supplies 42,617 63,062 Total Inventory 741,216 741,978 Reserve for Expiring Inventory (275,701 ) (223,400 ) Inventory, net $ 465,515 $ 518,578

Property and Equipment

Property and Equipment	6 Months Ended
	Jun. 30, 2023
Property and Equipment [Abstract]
PROPERTY AND EQUIPMENT	4. PROPERTY AND EQUIPMENT As of June 30, 2023 and December 31, 2022, Property and Equipment consists of: June 30, December 31, Lab Equipment $ 132,911 $ 132,911 Computer Equipment 12,261 12,261 Furniture 3,030 3,030 Property and Equipment, at Cost 148,202 148,202 Accumulated depreciation (140,704 ) (126,902 ) Property and Equipment, Net $ 7,498 $ 21,300 Depreciation expenses for Property and Equipment for the six months ended June 30, 2023 and 2022 were in the amount of $13,802 and $13,846, respectively ($6,901 for both the three months ended June 30, 2023 and 2022).

Intangible Assets

Intangible Assets	6 Months Ended
	Jun. 30, 2023
Intangible Assets [Abstract]
INTANGIBLE ASSETS	5. INTANGIBLE ASSETS As of June 30, 2023 and December 31, 2022, Intangible Assets consist of: June 30, December 31, Patents $ 161,032 $ 145,613 Website Development Costs 66,965 27,070 Intangible Assets, at Cost 227,997 172,683 Accumulated Amortization (21,620 ) (8,428 ) Intangible Assets, Net $ 206,377 $ 164,255 Amortization expense for the six months ended June 30, 2023, and 2022 was in the amount of $13,192 and $1,962, respectively ($6,017 and $952 for the three months ended June 30, 2023 and 2022, respectively). The following table summarizes the estimated future amortization expense for our patents and website development costs as of June 30, 2023: Period Patents Website 2023 (remaining six months) $ 1,996 $ 10,161 2024 3,991 20,322 2025 3,991 17,208 2026 3,991 411 Thereafter 31,589 - Total $ 45,558 $ 48,102 The Company additionally has $109,241 in capitalized patent expenses that will be amortizable as the patents they are associated with are awarded.

Capitalization and Equity Trans

Capitalization and Equity Transactions	6 Months Ended
	Jun. 30, 2023
Capitalization and Equity Transactions [Abstract]
CAPITALIZATION AND EQUITY TRANSACTIONS	6. CAPITALIZATION AND EQUITY TRANSACTIONS Shareholder Shares On June 1, 2022, 60P LLC entered into the Agreement and Plan of Merger with 60 Degrees Pharmaceuticals, Inc., pursuant to which 60P LLC merged into 60 Degrees Pharmaceuticals, Inc. (the “Merger”). The value of each outstanding member’s membership interest in 60P LLC was correspondingly converted into common stock of 60 Degrees Pharmaceuticals, Inc., par value $0.0001 per share, with a cost basis equal to $5 per share. On June 30, 2022 the Company issued 37,067 shares of common stock to its Chief Executive Officer for $185,335 at a purchase price of $5 per share. In January and March 2023, the Board of Directors, with the consent of Tyrone Miller and Geoffrey S. Dow, respectively, approved resolutions to cancel an aggregate of 192,101 shares of common stock issued to Tyrone Miller and 1,258,899 shares of common stock issued to the Geoffrey S. Dow Revocable Trust to allow the Company to issue new shares to vendors in exchange for valuable services to be provided for use in the Company’s operations. The cancelled shares represented approximately 61% of the issued and outstanding shares as of December 31, 2022. During the six months ended June 30, 2023, the Company issued a total of 1,443,000 shares of common stock to certain vendors as payment for services rendered or to be provided to the Company (0 during the three months ended June 30, 2023). As of June 30, 2023, 2,378,009 shares have been issued and were outstanding.

Deferred Compensation

Deferred Compensation	6 Months Ended
	Jun. 30, 2023
Deferred Compensation [Abstract]
DEFERRED COMPENSATION	7. DEFERRED COMPENSATION In 2020, the Company received consulting services from Biointelect Pty Ltd. of Australia (“Biointelect”) with a value of $100,000, which is payable contingent upon a future capital raise and is non-interest bearing. On May 5, 2022, the Company agreed to modify their contract with Biointelect. Previously, Biointelect potentially could earn $60,000 in deferred cash compensation and $400,000 in warrants in connection with a fundraise and other services provided. As the Company considered this compensation unlikely, it agreed to restructure by increasing the cash component to $100,000, tying $155,000 in equity compensation to an IPO or future qualifying transaction while leaving $245,000 in equity compensation with the original triggering events. The Company recognized a deferred compensation charge for the $155,000 in equity compensation during the three months ended June 30, 2022. Also in 2020, the Company entered into an agreement with Latham Biopharma for contingent compensation. On June 17, 2022 the Company and Latham Biopharma agreed to convert the $57,198 of deferred compensation that was earned and due and $12,500 of accrued expenses into a 100% contingent deferred compensation amount of $38,900 in cash and $60,000 in common shares of the Company if, within the next five years the Company nets at least $10,000,000 in an IPO or any private financing that secures the retirement and/or conversion to equity of all secured debt excluding the loans advanced by the Small Business Administration. Then before the year ended December 31, 2022, the Company and Latham Biopharma initiated an agreement that converted the entire deferred compensation into 65,000 shares valued at $5 per share. As of December 31, 2022, the Company recognized a contingent liability related to the subsequent agreement of $325,000. On January 11, 2023, the Company issued 65,000 shares to Latham Biopharma in full satisfaction of its obligations with respect to the services provided.

Debt

Debt	6 Months Ended
	Jun. 30, 2023
Debt [Abstract]
DEBT	8. DEBT Promissory Notes Knight Therapeutics, Inc. On December 27, 2019 the Company restructured its cumulative borrowing with its senior secured lender, Knight Therapeutics, Inc. (‘Knight’), into a note for the principal amount of $6,309,823 and accrued interest of $4,160,918 and a debenture of $3,483,851 (collectively, the ‘Knight Loan’). The Knight Loan had a maturity date of December 31, 2023. The principal and accrued interest portion of the Knight Loan bear an annual interest rate of 15%, compounded quarterly, whereas the debenture had a 9% interest rate until April 23, 2023 at which point interest ceased accruing. As of December 31, 2022, the aggregate outstanding balance of the Knight Loan was $20,596,595. In January 2023, the Company and Knight executed the Knight Debt Conversion Agreement, pursuant to which the parties agreed to add a conversion feature to the cumulative outstanding Knight Loans, which was accounted for as a debt extinguishment, described further below. Note, including Amendment On October 11, 2017 the Company issued a promissory note (“Note”) with an individual investor in the amount of $750,000. The Note matures 60 days after the Knight Loans are repaid. The Note originally bore an interest rate of 5% from inception for the first six months and 10% per annum thereafter both compounded quarterly. On December 11, 2022, the Company and the individual investor amended the Note (“the Amendment”). The Amendment added a provision to automatically convert the outstanding principal and accumulated interest through March 31, 2022 into common shares in the event the Company consummates an IPO. The Amendment also provides the lender the option to convert the outstanding principal and accumulated interest through March 31, 2022 into equity shares of the Company at the maturity date, which option shall expire 30 days after maturity. Cumulative interest after March 31, 2022 will be forfeited should the lender elect to convert the Note into equity. At the Amendment date, the Company recorded a discount of $120,683 related to the excess fair value of the Note and incurred costs with third parties directly related to the Amendment of $1,767, which are being amortized over the remaining life of the debt using the effective interest method. Amortization of the discount on the Note for the three months ended June 30, 2023 and 2022 was $24,613 and $0, respectively ($48,759 and $0 for the six months ended June 30, 2023 and 2022, respectively). Interest expense related to the Note, for the three months ended June 30, 2023 and 2022 was $31,352 and $28,401, respectively ($61,614 and $55,813 for the six months ended June 30, 2023 and 2022, respectively). Pursuant to the terms of the Note, including the Amendment, in connection with the closing of the Company’s IPO on July 14, 2023, the outstanding principal and accrued interest related to the Note converted into shares of the Company’s common stock. See Note 12 for further details. Promissory notes are summarized as follows at June 30, 2023: Knight Therapeutics Note, including amendment Bridge Notes Total Promissory Notes (including accrued interest), at fair value $ 23,539,996 $ - $ - $ 23,539,996 Promissory Notes (including accrued interest) - 1,220,155 1,105,122 2,325,277 Less Current Maturities 23,539,996 - 1,105,122 24,645,118 Long Term Promissory Notes $ - $ 1,220,155 $ - $ 1,220,155 Promissory notes are summarized as follows at December 31, 2022: Knight Therapeutics Note, including amendment Bridge Notes Total Promissory Notes (including accrued interest), at fair value $ 16,319,986 1,109,783 535,901 17,965,670 Promissory Notes (including accrued interest) 16,319,986 - 535,901 16,855,887 Less Current Maturities - $ 1,109,783 $ - $ 1,109,783 Long Term Promissory Notes $ 16,319,986 1,109,783 535,901 17,965,670 Convertible Promissory Notes and Warrants During May 2022, the Company executed promissory notes having a face amount of $888,889. The notes contain an original issue discount of 10% ($88,889) and debt issuance costs of $91,436, resulting in net proceeds of $708,564. These notes bear interest at 10% with a default interest rate of 15% and are unsecured. The notes are due at the earlier of one year from the issuance date or the closing of an IPO (the “2022 Bridge Notes”). In connection with the issuance of the 2022 Bridge Notes, the Company will issue common stock to each noteholder equivalent to (a) 100% of the face amount of the note divided by the IPO price per share, or (b) if the Company fails to complete the IPO prior to May 24, 2023, the number of shares of the Company’s common stock calculated using a $27,000,000 pre-money valuation of the Company and the number of the Company’s outstanding shares of common stock on May 24, 2023. Additionally, each of these note holders are entitled to receive five-year (5) fully vested warrants upon the closing of an IPO, with an exercise price of 110% of the IPO price. In May 2023, the maturity date for the 2022 Bridge Notes was extended for an additional two months. During May 2023, the Company executed promissory notes having an aggregate face amount of $722,222. The notes contain an original issue discount of 10% ($72,222) and the Company incurred debt issuance costs of $95,000, resulting in net proceeds to the Company of $555,000. These notes bear interest at 10% with a default interest rate of 15% and are unsecured. The notes are due at the earlier of one-year from the issuance date or the closing of an IPO (the “2023 Bridge Notes”). In connection with the issuance of the 2023 Bridge Notes, the Company will also issue common stock to each note holder equivalent to (a) 100% of the face amount of the note divided by the IPO price per share, or (b) if the Company fails to complete the IPO prior to May 4, 2024, the number of shares of the Company’s common stock calculated using a $27,000,000 pre-money valuation of the Company and the number of the Company’s outstanding shares of common stock on May 4, 2024. Additionally, each of these noteholders are entitled to receive five-year (5) fully vested warrants upon the closing of an IPO, with an exercise price of 110% of the IPO price. The Company performed an evaluation of the conversion features embedded in the Bridge Notes and the warrants and concluded that such instruments qualify for treatment as derivative liabilities under ASC 815 and require bifurcation from the host contract. Derivative liabilities are carried at fair value at each balance sheet date, and any changes in fair value are recognized in the accompanying consolidated condensed statement of operations and comprehensive loss. See Note 9 for further details. Pursuant to the terms of the 2022 and 2023 Bridge Notes, in connection with the closing of the Company’s IPO on July 14, 2023, the outstanding principal and accrued interest related to the notes converted into shares of the Company’s common stock. See Note 12 for further details. Related Party Notes During May 2022, the Company executed convertible promissory notes with the Company’s Chief Executive Officer and a family member related to the Chief Executive Officer, having an aggregate face amount of $338,889. The notes contain an original issue discount of 10% ($33,888) and debt issuance costs of $34,289, resulting in net proceeds of $270,711. These notes bear interest at 6% with a default interest rate of 15% and are unsecured. The notes were due at the earlier of one-year (1) from the issuance date or the closing of an IPO (the “Related Party Notes”). In May 2023, the maturity date for the 2022 Bridge Notes was extended for an additional two months. Upon the closing of an IPO, these notes are mandatorily redeemable at the lesser of (a) 20% discount to the IPO price or (b) $27,000,000 pre-money valuation. Additionally, each of these note holders are entitled to receive five-year (5) fully vested warrants upon the closing of an IPO, with an exercise price of 110% of the IPO price. If the IPO is not completed by May 31, 2023, the exercise price is 90% of the IPO price. The Company performed an evaluation of the conversion features embedded in the Related Party Notes and the warrants and concluded that such instruments qualify for treatment as derivative liabilities under ASC 815 and require bifurcation from the host contract. See Note 9 for further details. Bridge Notes and Related Party Notes are summarized as follows at June 30, 2023 and December 31, 2022: 2022 Bridge Related Party 2023 Bridge Issuance date of promissory notes May 2022 May 2022 May 2023 Maturity date of promissory notes 1 1 1 Interest rate 10 % 6 % 10 % Default interest rate 15 % 15 % 15 % Collateral Unsecured Unsecured Unsecured Conversion rate 2 2 2 Face amount of notes $ 888,889 $ 338,889 $ - Less: unamortized debt discount (407,555 ) (155,443 ) - Add: accrued interest on promissory notes 54,567 11,651 - Balance - December 31, 2022 $ 535,901 $ 195,097 $ - Face amount of notes 888,889 338,889 722,222 Less: unamortized debt discount - - (638,100 ) Add: accrued interest on promissory notes 121,480 31,177 10,632 Balance - June 30, 2023 $ 1,010,369 $ 370,066 $ 94,754 1 2 For the six months ended June 30, 2023 and 2022, the Company recorded amortization of debt discounts of $645,336 and $326,396, respectively. Pursuant to the terms of the Related Party Notes, in connection with the closing of the Company’s IPO on July 14, 2023, the outstanding principal and accrued interest converted into shares of common stock. See Note 12 for further details. Knight Debt Conversion On January 9, 2023, and in two subsequent amendments, the Company and Knight Therapeutics agreed to extinguish Knight’s debt in the event of an IPO. Key points of this agreement are as follows: ● The Parties agreed to fix Knight’s cumulative debt to the value as it stood on March 31, 2022, which consisted of $10,770,037 in principal and $8,096,486 in accumulated interest should the Company execute an IPO that results in gross proceeds of at least $7,000,000 prior to December 31, 2023. Should an IPO not occur by January 1, 2024 then all terms of the original debt would resume including any interest earned after March 31, 2022. ● The Parties agreed to convert the fixed principal amount into (i) that number of shares of common stock equal to dividing the principal amount by an amount equal to the offering price of the common stock in the IPO discounted by 15%, rounding up for fractional shares, in a number of common shares up to 19.9% of the Company’s outstanding common stock after giving effect of the IPO; (ii) the Company will make a milestone payment of $10 million to Knight if, after the date of a Qualifying IPO, the Company sells Arakoda™ or if a Change of Control (as per the definition included in the original loan agreement dated on December 10, 2015) occurs, provided that the purchaser of Arakoda™ or individual or entity gaining control of the Borrower is not the Lender or an affiliate of the Lender; (iii) following the License and Supply agreement dated on December 10, 2015 and subsequently amended on January 21, 2019, an expansion of existing distribution rights to tafenoquine/Arakoda™ to include COVID-19 indications as well as malaria prevention across the Territory as defined in said documents, subject to US Army approval; and (iv) Company will retain Lender or an affiliate to provide financial consulting services, management, strategic and/or regulatory advice of value $30,000 per month for five years (the parties will negotiate the terms of that consulting agreement separately in good faith). ● The parties agreed to convert the accrued interest into that number of shares of a new class of preferred stock (the “Preferred Stock”) by dividing the fixed accumulated interest by $100.00, then rounding up. The Preferred Stock shall have the following rights, preferences, and designations: (i) have a 6% cumulative dividend accumulated annually on March 31; (ii) shall be non-voting stock; (iii) are not redeemable, (iv) be convertible to shares of common stock at a price equal to the lower of (1) the price paid for the shares of common stock in the initial public offering and (2) the 10 day volume weighted average share price immediately prior to conversion; and (v) conversion of the preferred stock to common shares will be at the Company’s sole discretion. Notwithstanding the foregoing, the Preferred Stock shall not be converted into shares of common stock if as a result of such conversion Knight will own 19.9% or more of our outstanding common stock. ● In addition to the conversion of the debt, for a period commencing on January 1, 2022 and ending upon the earlier of 10 years after the Closing or the conversion or redemption in full of the Preferred Stock, Company shall pay Lender a royalty equal to 3.5% of the Company’s net sales (the “Royalty”), where “Net Sales” has the same meaning as in the Company’s license agreement with the U.S. Army for tafenoquine. Upon success of the Qualified IPO, the Company shall calculate the royalty payable to Knight at the end of each calendar quarter. The Company shall pay to Knight the royalty amounts due with respect to a given calendar quarter within fifteen (15) business days after the end of such calendar quarter. Each payment of royalties due to Knight shall be accompanied by a statement specifying the total gross sales, the net sales and the deductions taken to arrive to net sales. For clarification purposes, the first royalty payment will be performed following the above instructions, on the first calendar quarter in which the Qualified IPO takes place and will cover the sales for the period from January 1, 2022 until the end of said calendar quarter. The Company evaluated the January 9, 2023 exchange agreement in accordance with ASC 470-50 and concluded that the debt qualified for debt extinguishment because a substantial conversion feature was added to the debt terms. Upon extinguishment, the Company recorded a loss upon extinguishment in the amount of $839,887 and elected to recognize the new debt under the ASC 825 fair value option until it is settled. A reconciliation of the beginning and ending balances for the Convertible Knight Note, which is measured at fair value on a recurring basis using significant unobservable inputs (Level 3) is as follows for the three and six months ended June 30, 2023: Convertible Knight Note, at fair value Promissory Notes, at fair value at December 31, 2022 $ - Fair value at modification date - January 9, 2023 21,520,650 Fair value - mark to market adjustment (339,052 ) Accrued interest recognized 634,243 Promissory Notes, at fair value at March 31, 2023 21,815,841 Fair value - mark to market adjustment 1,064,849 Accrued interest recognized 659,306 Promissory Notes, at fair value at June 30, 2023 $ 23,539,996 From the modification date of January 9, 2023 to June 30, 2023, the Company recorded a net increase in the fair of the Convertible Knight Note of $725,797 and recorded additional interest expense of $1,293,549. Pursuant to the Knight Debt Conversion Agreement, in connection with the closing of the Company’s IPO on July 14, 2023, the outstanding principal and accumulated interest as of March 31, 2022 converted into shares of common stock and Series A Preferred Stock, respectively. See Note 12 for further details. Debenture On April 24, 2019, 60P entered into the Knight debenture of $3,000,000 with an original issue discount of $2,100,000, which was being amortized using the effective interest method. The Company subsequently restructured the Knight Loans, including the debenture, pursuant to the Knight Debt Conversion Agreement (see above). $13,696 of the original issue discount was amortized to interest expense in 2023 prior to the amendment ($240,850 during the six months ended June 30, 2022) and the unamortized original issue discount at June 30, 2023 was $0 ($279,061 at December 31, 2022) as a result of the debt conversion (discussed above), which was accounted for as a debt extinguishment. The Knight debenture as of June 30, 2023 and December 31, 2022 consisted of the following: June 30, December 31, Original Debenture $ - $ 3,000,000 Unamortized debt discount - (279,061 ) Debenture Prior to Accumulated Interest - 2,720,939 Accumulated Interest - 1,555,670 Debenture $ - $ 4,276,609 SBA COVID-19 EIDL On May 14, 2020, the Company received COVID-19 EIDL lending from the Small Business Administration (SBA) in the amount of $150,000. The loan bears interest at an annual rate of 3.75% calculated on a monthly basis. The Company was committed to make $731 monthly payments first due June 4, 2021. On March 31, 2021, the SBA announced the deferment period has been extended an additional eighteen months. Thus, the Company was first obligated to start making interest payments of $731 on November 4, 2022. The balance as of June 30, 2023 is $161,366 ($163,022 at December 31, 2022). The current maturity at June 30, 2023 is $8,772 and the long-term liability is $152,594 ($2,750 and $160,272 at December 31, 2022, respectively). The current future payment obligations of the principal are as follows: Period Principal Payments 2023 (remaining six months) $ - 2024 - 2025 - 2026 - 2027 2,804 Thereafter 147,196 Total $ 150,000 Due to the deferral, the Company is expected to make a balloon payment of $32,383 to be due on 10/12/2050. Related Party Advances In March 2023, the Company received a $200,000 short term advance from the Geoffrey S. Dow Revocable Trust. In April 2023, the Company received $50,000 as a short-term advance from management. The Geoffrey S. Dow Revocable Trust contributed $23,000 and Tyrone Miller contributed $27,000. On May 11, 2023, these short term advances were refunded in full for an aggregate amount of $250,000.

Derivative Liabilities

Derivative Liabilities	6 Months Ended
	Jun. 30, 2023
Derivative Liabilities [Abstract]
DERIVATIVE LIABILITIES	9. DERIVATIVE LIABILITIES As discussed in Note 8 above, certain of the Company’s bridge shares, warrants and convertible notes (containing an embedded conversion feature) are accounted for as derivative liabilities as there is an unknown exercise price associated with each instrument. The exercise price is dependent upon a yet to be completed IPO or a failed IPO. In both cases, the possible exercise prices contain different conditions (related to the success or failure of the IPO) that could result in issuing an undeterminable number of shares of common stock upon settlement. In accordance with ASC 815, derivative liabilities are initially measured at fair value at the commitment date and subsequently remeasured at each reporting period, with any increase or decrease in the fair value recorded in the results of operations within other income/expense as the change in fair value of derivative liabilities. In connection with the valuation of the Company’s derivative liabilities related to the 2022 Bridge Notes and warrants, the Company determined a fair value on the commitment date (May 24, 2022) of $1,483,888. As the fair value of the derivative liabilities exceeded the net proceeds received of $979,275, the Company recorded a debt discount at the maximum amount allowed (the face amount of the debt less the OID and debt issuance costs, as detailed in Note 8), which required the excess to be recorded as a derivative expense. Derivative expense recorded during the three and six months ended June 30, 2022 is summarized as follows: Commitment Date May 24, Fair value of derivative liabilities $ 1,483,888 Less: face amount of debt (979,275 ) Derivative expense $ 504,613 In connection with the valuation of the Company’s derivative liabilities related to the 2023 Bridge Notes and warrants, the Company determined a fair value on the commitment date (May 8, 2023) of $954,725. As the fair value of the derivative liabilities exceeded the net proceeds received of $555,000, the Company recorded a debt discount at the maximum amount allowed (the face amount of the debt less the OID and debt issuance costs detailed in Note 8) and recorded the excess as derivative expense. Derivative expense recorded during the three and six months ended June 30, 2023 is summarized as follows: Commitment Date May 8, Fair value of derivative liabilities $ 954,725 Less: face amount of debt (555,000 ) Derivative expense $ 399,725 A reconciliation of the beginning and ending balances for the derivative liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) is as follows at June 30, 2023 and December 31, 2022: Bridge Warrants Convertible Total Derivative liabilities - December 31, 2022 $ 834,352 $ 578,164 $ 81,684 $ 1,494,200 Fair value - mark to market adjustment 4,902 1,689 (1,457 ) 5,134 Derivative liabilities - March 31, 2023 $ 839,254 $ 579,853 $ 80,227 $ 1,499,334 Fair value - commitment date 680,276 274,449 - 954,725 Fair value - mark to market adjustment 8,896 (17,009 ) 145 (7,968 ) Derivative liabilities - June 30, 2023 $ 1,528,426 $ 837,293 $ 80,372 $ 2,446,091 A reconciliation of the beginning and ending balances for the derivative liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) is as follows at June 30, 2022 and December 31, 2021: Bridge Warrants Convertible Total Derivative liabilities - December 31, 2021 $ - $ - $ - $ - Fair value - commitment date 823,687 565,007 95,194 1,483,888 Fair value - mark to market adjustment 664 2,932 (2,595 ) 1,001 Derivative liabilities - June 30, 2022 $ 824,351 $ 567,939 $ 92,599 $ 1,484,889 Changes in fair value of derivative liabilities (mark to market adjustment) are included in other income (expense) in the accompanying consolidated condensed statements of operations and comprehensive loss. During the three and six months ended June 30, 2023, the Company recorded a net change in the fair of derivative liabilities of $7,968 and $2,834, respectively. From the commitment date of May 8, 2022 to June 30, 2022, the Company recorded a net change in the fair value of derivative liabilities of ($1,001). On the respective commitment dates (Day 1 valuation), the fair value of the Company’s potential future issuances of common stock related to common stock issued with promissory notes, warrants and embedded conversion features in convertible promissory notes is established with an estimate using the Monte Carlo Simulation Model to compute fair value. The Monte Carlo simulation requires the input of assumptions, including our stock price, the volatility of our stock price, remaining term in years, expected dividend yield, and risk-free rate. In addition, the valuation model considers the probability of the occurrence or nonoccurrence of an IPO within the terms of liability-classified financial instruments, as an IPO event can potentially impact the settlement. At each subsequent reporting period, we remeasure the fair value of liability-classified bridge shares, warrants and embedded conversion features in convertible promissory notes using the Monte Carlo simulation. The assumptions used to perform the Monte-Carlo Simulation as of the respective commitment dates as well as June 30, 2023 and December 31, 2022 were as follows: Commitment Dates May 2023 May 2022 Stock price $ 5.30 $ 5.00% Volatility 115.1% 99.7% Expected term (in years) - Notes 0.99 1.00-1.03 Expected term (in years) - Warrants 4.99 5.00% Risk-free interest rate 4.80% 2.76% - 2.84 Dividend yield 0% 0% IPO probability (prior to note maturity date) 95% 95% Mark to Market June 30, December 31, Stock price $ 5.30 $ 5.00 Volatility 100.3% - 104.3% 101.9% Expected term (in years) - Notes 0.05 - 0.85 0.39 - 0.41 Expected term (in years) - Warrants 3.89 - 4.85 4.39 Risk-free interest rate 4.16% - 4.33 4.06% Dividend yield 0% 0% IPO probability (prior to note maturity date) 95% 95%

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2023
Income Taxes [Abstract]
INCOME TAXES	10. INCOME TAXES The Company did not record a federal income tax provision or benefit for each of the three and six months ended June 30, 2023 and 2022 due to losses. The Company recorded a provision for income taxes for DC of $63 and $126 for the three and six months ended June 30, 2023, respectively, thereby reflecting the minimum statutory tax due ($250 and $500 for the three and six months ended June 30, 2022, respectively).

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2023
Commitments and Contingencies [Abstract]
COMMITMENTS AND CONTINGENCIES	11. COMMITMENTS AND CONTINGENCIES Operating Lease On February 3, 2016, and subsequently amended, the Company entered into the lease agreement with CXI Corp to rent business premises. In January 2023, the lease was extended for an additional twelve-month term until March 31, 2024. The Company applies ASC 842 to its operating leases, which are reflected on the consolidated condensed balance sheets within Right of Use (ROU) Asset and the related current and non-current operating lease liabilities. ROU assets represent the right to use an underlying asset for the lease term, and lease liabilities represent the obligation to make lease payments arising from lease agreement. Operating lease expense is recognized on a straight-line basis over the lease term, subject to any changes in the lease or expectation regarding the terms. Variable lease costs such as common area maintenance, property taxes and insurance are expensed as incurred. Future minimum lease payments on a discounted and undiscounted basis under the Company’s operating lease are as follows: Undiscounted Cash Flows Discount rate 15.00 % 2023 (remaining six months) $ 27,985 2024 13,992 Thereafter - Total undiscounted minimum future payments 41,977 Imputed interest (2,507 ) Total operating lease payments 39,470 Short-term lease liabilities 39,470 Long-term lease liabilities $ - Other information related to our operating lease is as follows: June 30, Weighted average remaining lease term (in years) 0.75 Weighted average discount rate 15.00 % Operating lease costs were in the amount of $13,859 and $12,974 for the three months ended June 30, 2023, and June 30, 2022, respectively ($27,366 and $25,947 for the six months ended June 30, 2023, and June 30, 2022, respectively). Board of Directors In November and December 2022, the Company signed agreements with four director nominees (Cheryl Xu, Paul Field, Charles Allen and Stephen Toovey) which come into effect on the date the Company’s Registration Statement is declared effective. As described in Note 1, the Company’s Registration Statement was declared effective on July 11, 2023. Each director will receive cash compensation of $11,250 quarterly. In addition, the two non-audit committee chairs (Toovey, Field) will receive $1,250 per quarter and the audit committee chair (Allen) will receive an additional $2,000 per quarter. Each director will receive a one-off issuance of common stock of value $50,000 and a non-qualified option to purchase an additional $50,000 of common stock. Each director will receive equity compensation in the form of restricted stock units valued at $40,000 and a non-qualified option to purchase $40,000 of common stock. Contingencies The Company’s operations are subject to a variety of local and state regulations. Failure to comply with one or more of those regulations could result in fines, restrictions on its operations, or losses of permits that could result in the Company ceasing operations. Contingent Compensation Prior to 2015 the Company agreed with certain vendors, advisors and employees to deferred compensation that expires on December 31, 2023. The net amount of these contingent payments is $43,581. The Company does not anticipate the trigger for these payments to be reached prior to expiration. In 2020, the Company engaged with two vendors to help secure COVID-19 trial funding for the Company’s Phase II COVID trial. Ultimately, the efforts were unsuccessful but a tail does remain. If one Australian fund participates in the Company’s IPO a maximum amount of $305,000 would be due as of June 30, 2023. The Company is not engaged with the Australian fund to solicit their participation in the Company’s IPO as of June 30, 2023. Litigation, Claims and Assessments From time to time, the Company may be involved in litigation relating to claims arising out of operations in the normal course of business. As of June 30, 2023, there were no pending or threatened lawsuits that could reasonably be expected to have a material effect on the results of the Company’s operations.

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2023
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	12. SUBSEQUENT EVENTS The Company has evaluated subsequent events through August 25, 2023, which is the date the financial statements were issued. In connection with the closing of the Company’s IPO on July 14, 2023. as discussed in Note 1, the following events occurred on July 11, 2023: ● The Registration Statement was declared effective by the SEC. ● As a result of the effectiveness of the Registration Statement, the Company issued a total of 40,000 restricted shares of common stock to the following directors and in the amounts listed: (i) Stephen Toovey (10,000 restricted shares of common stock), (ii) Charles Allen (10,000 restricted shares of common stock), (iii) Paul Field (10,000 restricted shares of common stock) and (iv) Cheryl Xu (10,000 restricted shares of common stock), by virtue of the terms of the agreements discussed in Note 11. On July 12, 2023, the following events occurred: ● The Company entered into an Underwriting Agreement with WallachBeth Capital LLC (the “Underwriter”), as representative of the underwriters of the IPO, pursuant to which the Company granted the underwriters a 45-day over-allotment option to purchase up to 212,265 shares of the Company’s common stock at a price of $5.28 per share and/or 212,265 tradeable warrants at a price of $0.01 per tradeable warrant and/or 212,265 non-tradeable warrants at $0.01 per non-tradeable warrant, or any combination thereof. ● The Company executed a Warrant Agent Agreement with Equity Stock Transfer, LLC, acting as warrant agent for the IPO, of which sets forth the procedures for registering, transferring and exercising the tradeable warrants and non-tradeable warrants. ● The shares of the Company’s common stock and tradeable warrants began trading on The Nasdaq Capital Market under the symbols “SXTP” and “SXTPW,” respectively. On July 13, 2023, the following events occurred: ● The Company received $183,336 from the exercise of 31,447 bridge warrants (strike price $5.83 and issued 31,447 new shares of common stock). On July 14, 2023, the following events occurred: ● The IPO closed, generating approximately $6,454,300 in net proceeds from the IPO after deducting the underwriting discount and commission and other estimated IPO expenses. The Underwriter partially exercised the over-allotment option and purchased an additional 100,644 tradeable warrants and 100,644 non-tradeable warrants. ● As a result of the completion of the IPO and as required under the terms of the agreement with BioIntelect as discussed in Note 7, the Company issued 29,245 shares of common stock to BioIntelect as deferred equity compensation valued in the amount of $155,000. ● As a result of the completion of the IPO and as required under the terms of the Bridge Notes from both 2022 and 2023 and the Related Party Notes described in Note 8, the entirety of the related outstanding principal in the amount of $1,950,000 converted to 383,908 shares of our common stock at the conversion prices detailed in Note 8 and made cash payments totaling approximately $1.8 million for the outstanding principal (2022 and 2023 Bridge Notes only), accrued interest, and the extension payments described in Note 8, in full satisfaction of the outstanding debt obligations. The Company expects to recognize a gain/loss of approximately $650,000 upon conversion. ● As a result of the completion of the IPO and as required under the terms of the Xu Yu Note, including the Amendment (discussed in Note 8), the entirety of the related outstanding principal and accrued interest converted to 214,934 shares of our common stock at the conversion price detailed in Note 8 and issued the common stock to investor, in full satisfaction of the outstanding debt obligation. The Company expects to recognize a gain of approximately $90,000 upon conversion. ● As a result of the completion of the IPO and as required under the terms of the Knight Debt Conversion Agreement detailed in Note 8, the cumulative outstanding principal and accrued interest as of March 31, 2022 converted to 1,108,337 shares of common stock and 80,965 shares of Series A Preferred Stock, respectively, at the conversion prices detailed in Note 8, and issued the common stock and Series A Preferred Stock to Knight, in full satisfaction of the Company’s obligations with respect to the principal amount and accumulated interest. The Company expects to recognize a gain of approximately $9.6 million upon conversion. ● The Company granted the Underwriter warrants to purchase a total of 84,906 shares of common stock, which shall expire on the fifth anniversary of the consummation of the IPO. ● The Company granted Geoff Dow, the Company’s President and Chief Executive Officer, a five-year option to purchase a total of 15,000 shares of the Company’s common stock on the last day of each quarter (for a cumulative total of no more than 300,000 shares over five years). The exercise price is the closing price of the stock on the day of the IPO. ● The Company granted Tyrone Miller, the Company’s Chief Financial Officer, a five-year option to purchase a total of 12,000 shares of the Company’s common stock on the last day of each quarter (for a cumulative total of no more than 240,000 shares over five years). The exercise price is the closing price of the stock on the day of the IPO. ● The Company received $381,600 from the exercise of 60,000 tradeable warrants (strike price $6.36) and issued 60,000 new shares of common stock. On July 17, 2023, the following event occurred: ● The Company accepted the exercise of 93,000 non-tradeable warrants (strike price $6.095), received $566,835 and issued 93,000 new shares of common stock. After this transaction the Company had 5,753,975 common shares outstanding. On July 25, 2023, the following event occurred: ● The Company converted 2,162 of Knight’s preferred shares in order to issue 45,560 new common shares. After the transaction Knight owned 78,803 preferred shares and 1,153,897 common shares (the latter representing 19.9% of the 5,799,535 common shares outstanding). On August 2, 2023, the following event occurred: ● Geoffrey Dow assigned his interest in 60P Australia Pty Ltd, of 904,436 common shares to 60P, Inc. for $0 consideration, thereby increasing the proportional ownership of 60P, Inc. in 60P Australia Pty Ltd from 87.53% to 96.61%. The purpose of this assignment was to eliminate the related party conflict associated with Geoffrey Dow’s ultimate beneficial ownership in 60P Australia Pty Ltd being greater than that of other 60P, Inc. shareholders. On August 9, 2023, the following events occurred: ● 60P, Inc. signed research & development/IP and loan agreements with its subsidiary, 60P Australia Pty Ltd, in which 60P, Inc. will provide up to $17 million AUD in financing (8% interest, repayment over ten years) and rights to use its patents and data to support the development of the COVID-19 treatment indication for tafenoquine in exchange for the subsidiary conducting COVID-19 clinical trials and being granted commercialization rights for the indication outside the United States. ● 60P Australia Pty Ltd engaged Peachtree Bioresearch Solutions to be its contract research organization for its planned COVID-19-tafenoquine Phase IIB treatment study and the Company authorized payment of $1,000,974 in start-up costs to open the first three clinical sites. On August 14, 2023, the following event occurred: ● 60P Australia Pty Ltd filed the Phase IIB study protocol for COVID-19-tafenoquine study against its new IND. On August 24th, 2023, the following event occurred: ● The Company's majority-owned subsidiary, 60P Australia Pty Ltd, filed an application for an Overseas Finding of R+D Activities related to its planned tafenoquine-COVID-19 research program with AusIndustry. There have been no other events or transactions during this time which would have a material effect on these financial statements.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	6 Months Ended
	Jun. 30, 2023
Summary of Significant Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The financial statements of 60P and its subsidiaries are prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). The Company has prepared the accompanying consolidated condensed financial statements pursuant to the instructions to Form 10-Q and Article 8 of Regulation S-X of the Securities and Exchange Commission (“SEC”). These financial statements are unaudited and, in our opinion, include all adjustments consisting of normal recurring adjustments and accruals necessary for a fair presentation of our consolidated condensed balance sheets, consolidated condensed statements of operations and other comprehensive loss, consolidated condensed statements of shareholders’ and member’s deficit and consolidated condensed statements of cash flows for the periods presented. Operating results for the periods presented are not necessarily indicative of the results that may be expected for the year ending December 31, 2023 due to various factors. Certain information and footnote disclosures normally included in complete financial statements prepared in accordance with U.S. GAAP have been omitted in accordance with the rules and regulations of the SEC. These consolidated condensed financial statements should be read in conjunction with the audited consolidated financial statements and related notes thereto as contained in the Company’s Registration Statement.
Principles of Consolidation and Noncontrolling Interest	Principles of Consolidation and Noncontrolling Interest The Company’s consolidated condensed financial statements include the financial statements of its majority owned (87.53%) subsidiary 60P Australia Pty Ltd, as well as the financial statements of 60P Singapore Pty Lte, a wholly owned subsidiary of 60P Australia Pty Ltd. All significant intercompany accounts and transactions have been eliminated in consolidation. 60P Singapore Pty Lte was closed via dissolution as of March 31, 2022. 60P Singapore Pty Lte was originally set up to conduct research in Singapore. The entity had no assets and its liabilities were to both 60P Australia Pty Ltd, its direct owner, and 60P. Through consolidation accounting the closure of the business unit resulted in a currency exchange gain. For entities that are consolidated, but not 100% owned, a portion of the income or loss and corresponding equity is allocated to owners other than the Company. The aggregate of the income or loss and corresponding equity that is not owned by us is included in Noncontrolling Interest in the consolidated financial statements.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates, and those estimates may be material. Significant estimates include the reserve for inventory, deferred compensation, derivative liabilities, certain promissory notes carried at fair value, and valuation allowance for the deferred tax asset.
Cash and Cash Equivalents	Cash and Cash Equivalents Cash and cash equivalents include all cash in banks and short-term highly liquid investments (with original maturities of three months or less) as cash equivalents. The Company’s cash is deposited in demand accounts at financial institutions that management believes are creditworthy. The Company’s cash and cash equivalents in bank deposit accounts, at times, may exceed federally insured limits. On June 30, 2023, the Company’s cash and cash equivalents did not exceed FDIC insured limits (did not exceed FDIC insured limits at December 31, 2022). The Company also held cash at its subsidiary in Australia though the amounts were minimal. The Company has not experienced any losses related to amounts in excess of FDIC limits. The Company does not hold any cash equivalents, which would consist of highly liquid investments with original maturities of three months or less at the time of purchase.
Accounts Receivable and Allowance for Doubtful Accounts	Accounts Receivable and Allowance for Doubtful Accounts The Company records accounts receivable at net realizable value. This value includes an appropriate allowance for estimated uncollectible accounts to reflect any loss anticipated on the trade accounts receivable balances and charged to the provision for doubtful accounts. Based on the Company’s history there has been no need to make a recording to Allowance for Doubtful Accounts. Most of the Company’s revenue has been earned via government contracts, and with a large American pharmaceutical distributor. As the Company continues to engage with smaller distributors, we will continue to analyze whether an allowance should be established. There was no allowance as of June 30, 2023 and December 31, 2022. At June 30, 2023, the US government accounted for 24% of the outstanding Accounts Receivable balance (66% at December 31, 2022) and the American pharmaceutical distributor accounted for 76% of the outstanding Accounts Receivable balance (30% for the year ended December 31, 2022).
Inventory	Inventory Inventories are stated at the lower of cost or net realizable value. Cost is comprised of direct materials and, where applicable, costs that have been incurred in bringing the inventories to their present location and condition. The Company uses the Specific Identification method per lot. A box price is calculated per lot number and sales are recognized by their lot number.
Property and Equipment	Property and Equipment Property and equipment are stated at cost. Normal repairs and maintenance costs are charged to earnings as incurred and additions and major improvements are capitalized. The cost of assets retired or otherwise disposed of and the related depreciation are eliminated from the accounts in the period of disposal and the resulting gain or loss is credited or charged to earnings. Depreciation is computed over the estimated useful lives of the related asset type or term of the operating lease using the straight-line method for financial statement purposes. The estimated service lives for Property and Equipment is either three (3), five (5) or seven (7) years.
Impairment of Long-lived Assets	Impairment of Long-lived Assets Long-lived assets, such as property and equipment and identifiable intangibles with finite useful lives, are periodically evaluated for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. We look for indicators of a trigger event for asset impairment and pay attention to any adverse change in the extent or manner in which the asset is being used or in its physical condition. Assets are grouped and evaluated for impairment at the lowest level of which there are identifiable cash flows, which is generally at a location level. Assets are reviewed using factors including, but not limited to, our future operating plans and projected cash flows. The determination of whether impairment has occurred is based on an estimate of undiscounted future cash flows directly related to the assets, compared to the carrying value of the assets. If the sum of the undiscounted future cash flows of the assets does not exceed the carrying value of the assets, full or partial impairment may exist. If the asset’s carrying amount exceeds its fair value, an impairment charge is recognized in the amount by which the carrying amount exceeds the fair value of the asset. Fair value is determined using an income approach, which requires discounting the estimated future cash flows associated with the asset.
Intangible Assets	Intangible Assets The Company capitalizes its patent and filing fees and legal patent and prosecution fees in connection with internally developed pending patents. When pending patents are issued, patents will be amortized over the expected period to be benefitted, not to exceed the patent lives, which may be as long as ten to fifteen years.
Website Development Costs	Website Development Costs The Company accounts for website development costs in accordance with ASC 350-50 “Website Development Costs”. Accordingly, all costs incurred in the planning stage are expensed as incurred, costs incurred in the website application and infrastructure development stage that meet specific criteria are capitalized and costs incurred in the day-to-day operation of the website are expensed as incurred. All costs associated with the websites are subject to straight-line amortization over a three-year period. During the three and also for the six months ended June 30, 2023, the Company capitalized website development or related costs of $6,000 and $39,895, respectively, in connection with the upgrade and enhancement of functionality of the corporate website at www.60-p.com ($0 and $0 for the three and six months ended June 30, 2022, respectively).
Derivative Liabilities	Derivative Liabilities The Company assessed the classification of its derivative financial instruments as of June 30, 2023 and December 31, 2022, which consist of bridge shares, convertible notes payable and certain warrants (excluding those for compensation) and has determined that such instruments qualify for treatment as derivative liabilities as they meet the criteria for liability classification under ASC 815. The Company analyzes all financial instruments with features of both liabilities and equity under the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic No. 480, (“ASC 480”), Distinguishing Liabilities from Equity and FASB ASC Topic No. 815, Derivatives and Hedging (“ASC 815”). Derivative liabilities are adjusted to reflect fair value at each reporting period, with any increase or decrease in the fair value recorded in the results of operations (other income/expense) as change in fair value of derivative liabilities. The Company uses a Monte Carlo Simulation Model to determine the fair value of these instruments. Upon conversion or repayment of a debt or equity instrument in exchange for shares of common stock, where the embedded conversion option has been bifurcated and accounted for as a derivative liability (generally convertible debt and warrants), the Company records the shares of common stock at par value, relieves all related debt, derivative liabilities, and debt discounts, and recognizes a net gain or loss on debt extinguishment. In connection with the debt extinguishment, the Company typically records an increase to additional paid-in capital for any remaining liability balance. Equity instruments that are initially classified as equity that become subject to reclassification under ASC Topic 815 are reclassified to liabilities at the fair value of the instrument on the reclassification date.
Original Issue Discount (“OID”)	Original Issue Discount (“OID”) For certain notes issued, the Company may provide the debt holder with an original issue discount. The original issue discount is recorded as a debt discount and is amortized to interest expense using the effective interest method over the life of the debt in the Consolidated Statements of Operations and Comprehensive Loss.
Debt Issuance Costs	Debt Issuance Costs Debt issuance costs paid to lenders, or third parties are recorded as debt discounts and amortized to interest expense over the life of the underlying debt instrument, in the Consolidated Statements of Operations and Comprehensive Loss, with the exception of certain debt for which we elected the fair value option. Debt issuance costs associated with debt for which the fair value option is elected are expensed as incurred.
Income Taxes	Income Taxes 60 Degrees Pharmaceuticals, Inc. is a corporation and has accepted the default taxation status of C corporation. The Merger in 2022 (See Note 6) did not materially impact tax matters as 60P LLC had elected to be taxed as a C corporation for income tax purposes at the beginning of 2022. The District of Columbia (“DC”) taxes corporations on form D-20 (DC Corporation Franchise Tax Return) and returns have a minimum tax due of $250 if gross receipts are at $1 million or less and a $1,000 if above. The tax years that remain subject to examination by major tax jurisdictions include the years ended December 31, 2019, 2020, 2021 and 2022. 60P Australia Pty Ltd. is subject to the taxes of the Australian Taxation Office and 60P Singapore Pte Ltd. was subject to the taxes of the Inland Revenue Authority of Singapore prior to its dissolution as of March 31, 2022. Management assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to use the existing deferred tax assets. On the basis of this evaluation, the Company has determined that it is more likely than not that the Company will not recognize the benefits of the foreign and state net deferred tax assets, and, as a result, full valuation allowance has been set against its net deferred tax assets as of June 30, 2023 and December 31, 2022. The Company recognizes the impact of a tax position in the financial statements if that position is more likely than not to be sustained on a tax return upon examination by the relevant taxing authority, based on the technical merits of the position. As of June 30, 2023, and December 31, 2022, the Company had no recognized tax benefits. The Company recognizes interest and penalties related to income tax matters as other expense and non-deductible penalties, respectively. As of June 30, 2023, the Company has recognized a potential tax penalty regarding a US foreign tax reporting form of $30,000 ($30,000 at December 31, 2022).
Concentrations	Concentrations Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash, accounts receivable, inventory purchases, and lending. Significant customers represent any customer whose business makes up 10% of our receivables or revenues. 100% of receivables as of June 30, 2023 (consisting of two significant customers at 76% and 24%) and 100% of total net revenues for the three months ended June 30, 2023 were generated by one significant customer (100% for the three months ended June 30, 2022 consisting of one significant customer). At December 31, 2022, 98% of the Company’s receivables, consisting of three customers and two significant at 59% and 39%, were generated from significant customers. 100% of the revenues were generated by the Company from one significant customer during the six months ended June 30, 2023 (100% for the six months ended June 30, 2022 consisting of one significant customer). Currently, the Company has exclusive relationships with distributors in Australia and Europe. A failure to perform by any of our current distributors would create disruption for patients in those markets. The US government has historically been the Company’s largest customer through a purchase support contract and a clinical study. Both of those activities ended during 2022 and near-term receivables and revenues from the government are not anticipated to be significant. Since the Company first started working on tafenoquine all inventory has been acquired in a collaborative relationship from a sole vendor. Should the vendor cease to supply tafenoquine it would take significant costs and efforts to rebuild the supply chain with a new sole vendor sourcing the active pharmaceutical ingredient (“API”). As of June 30, 2023, 84% (85% at December 31, 2022) of the Company’s non-related party debt is held by Knight Therapeutics, the senior secured lender and also a publicly traded Canadian company. The amount of senior secured debt with Knight Therapeutics currently limits the Company’s ability to access additional credit and management has been informed that additional lending with Knight Therapeutics is not currently possible.
Business Segments	Business Segments The Company uses the “management approach” to identify its reportable segments. The management approach requires companies to report segment financial information consistent with information used by management for making operating decisions and assessing performance as the basis for identifying the Company’s reportable segments. To date, the Company has managed its business in one identifiable segment.
Revenue Recognition	Revenue Recognition The Company recognizes revenue in accordance with FASB ASC Topic No. 606, Revenue from Contracts with Customers (“ASC 606”). Revenues are recognized when control is transferred to customers in amounts that reflect the consideration the Company expects to be entitled to receive in exchange for those goods. Revenue recognition is evaluated through the following five steps: (i) identification of the contract, or contracts, with a customer; (ii) identification of the performance obligations in the contract; (iii) determination of the transaction price; (iv) allocation of the transaction price to the performance obligations in the contract; and (v) recognition of revenue when or as a performance obligation is satisfied. The Company receives the majority of its revenues from sales of its Arakoda™ product to resellers in the US and abroad. The Company records US commercial revenues as a receivable when our American distributor transfers shipped product to their title model for 60P. Foreign sales to both Australia and Europe are recognized as a receivable at the point product is shipped to distributor. The shipments to Australia and Europe are further subject to profit sharing agreements for boxes sold to customers.
Research and Development	Research and Development Costs The Company accounts for research and development costs in accordance with FASB ASC Subtopic No. 730-10, Research and Development (“ASC 730-10”). Under ASC 730-10, research and development costs are expensed as incurred. Accordingly, internal research and development costs are expensed as incurred. Prepaid research and development costs are deferred and amortized over the service period as the services are provided. The Company recorded $203,872 and $327,866 in research and development costs expense during the three and six months ended June 30, 2023, respectively ($231,394 and $294,451 for the three and six months ended June 30, 2022, respectively). During the three and six months ended June 30, 2023, the Company deferred prepaid research and development costs in exchange for share-based payments of 525,000 common stock shares and 405,000 common stock shares to two nonemployees, Kentucky Technology Inc. and Florida State University Research Fund, Inc., respectively. The agreements with these nonemployees do not include any provisions to claw back the share-based payments in the event of nonperformance by the nonemployees. Subject to applicable federal and state security laws, the nonemployees can sell the received equity instruments. Kentucky Technology Inc. is expected to render research and development services to identify a combination drug partner for tafenoquine over a period of one year. Florida State University Research Fund, Inc. is expected to render research and development services related to development of celgosivir over a period of up to five years. At June 30, 2023, the Company recorded $3,130,000 current unamortized deferred prepaid research and development costs ($0 at December 31, 2022) and $1,431,092 non-current unamortized deferred prepaid research and development costs ($0 at December 31, 2022). Current unamortized deferred prepaid research and development costs are presented as a component of Prepaid and Other on the accompanying consolidated condensed balance sheets.
Fair Value of Financial Instruments and the Fair Value Option (“FVO”)	Fair Value of Financial Instruments and the Fair Value Option (“FVO”) The carrying value of the Company’s financial instruments included in current assets and current liabilities (such as cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses) approximate their fair value due to the short-term nature of such instruments. The inputs used to measure fair value are based on a hierarchy that prioritizes observable and unobservable inputs used in valuation techniques. These levels, in order of highest to lowest priority, are described below: Level 1 — Quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets or liabilities. Level 2 — Observable prices that are based on inputs not quoted on active markets but corroborated by market data. Level 3 — Unobservable inputs reflecting the Company’s assumptions, consistent with reasonably available assumptions made by other market participants. These valuations require significant judgment. The Company may choose to elect the FVO for certain eligible financial instruments, such as Promissory Notes, in order to simplify the accounting treatment. Items for which the FVO has been elected are presented at fair value in the consolidated balance sheets and any change in fair value unrelated to credit risk is recorded in other income in the consolidated statements of operations. Changes in fair value related to credit risk are recognized in other comprehensive income. The Company’s financial instruments recorded at fair value on a recurring basis at June 30, 2023, and December 31, 2022 include the certain convertible promissory notes for which the Company elected the FVO and Derivative Liabilities, which are carried at fair value based on Level 3 inputs. See Notes 8 and 9 regarding Promissory Notes, at fair value and Derivative Liabilities, respectively. Liabilities measured at fair value at June 30, 2023 and December 31, 2022 are as follows: June 30, 2023 Level 1 Level 2 Level 3 Total Liabilities: Promissory Notes (including accrued interest), at fair value $ - $ - $ 23,539,996 $ 23,539,996 Derivative Liabilities - - 2,446,091 2,446,091 Total $ - $ - $ 25,986,087 $ 25,986,087 December 31, 2022 Level 1 Level 2 Level 3 Total Liabilities: Derivative Liabilities $ - $ - $ 1,494,200 $ 1,494,200 Total $ - $ - $ 1,494,200 $ 1,494,200
Foreign Currency Transactions and Translation	Foreign Currency Transactions and Translation The individual financial statements of each group entity are measured and presented in the currency of the primary economic environment in which the entity operates (its functional currency). The consolidated financial statements of the group and the statement of financial position and equity of the company are presented in US dollars, which is the functional currency of the Company and the presentation currency for the consolidated financial statements. For the purpose of presenting consolidated financial statements, the assets and liabilities of the group’s foreign operations are mostly translated at exchange rates prevailing on the reporting date. Income and expense items are translated at the average exchange rates for the period, unless exchange rates fluctuate significantly during that period, in which case the exchange rates at the dates of the transactions are used. Exchange differences arising, if any, are recognized in other income. Exchange rates along with historical rates used in these financial statements are as follows: Average Exchange Rate Three Months Ended June 30, Six Months Ended June 30, As of Currency 2023 2022 2023 2022 June 30, December 31, 1 AUD = 0.6683 USD 0.7147 USD 0.6761 USD 0.7194 USD 0.6662 USD 0.6805 USD 1 SGD = NA 0.9950 AUD* NA 1.0150 AUD* NA 1.0230 AUD* * Through 4/30/2022 (account closure date)
Reclassifications	Reclassifications Certain prior period amounts have been reclassified for consistency with the current period presentation. These reclassifications had no material effect on the consolidated results of operations and comprehensive loss, shareholders’ and members’ deficit, or cash flows.
Accumulated Comprehensive Income (Loss)	Accumulated Comprehensive Income (Loss) Other comprehensive loss consists of foreign currency translation adjustments and unrealized gains and losses from cash flow hedges.
2022 Equity Incentive Plan	2022 Equity Incentive Plan On November 22, 2022, the Company adopted the 2022 Equity Incentive Plan also referred to as (“2022 Plan”). As of June 30, 2023, the maximum shares available under the 2022 Plan is equal to 238,601.
Share-Based Payments	Share-Based Payments The Company measures compensation for all share-based payment awards granted to employees, directors, and nonemployees, based on the estimated fair value of the awards on the date of grant. For awards that vest based on continued service, the service-based compensation cost is recognized on a straight-line basis over the requisite service period, which is generally the vesting period of the awards. For service vesting awards with compensation expense recognized on a straight-line basis, at no point in time does the cumulative grant date value of vested awards exceed the cumulative amount of compensation expense recognized. The Company accounts for forfeitures as they occur. For awards that vest upon a liquidity event or a change in control, the performance condition is not probable of being achieved until the event occurs. As a result, no compensation expense is recognized until the performance-based vesting condition is achieved, at which time the cumulative compensation expense will be recognized. For fully vested, nonforfeitable equity instruments that are granted at the date the Company and a nonemployee enter into an agreement for goods or services, the Company recognizes the equity instruments when they are granted. The corresponding cost is recognized as an immediate expense or a prepaid asset depending on the specific facts and circumstances of the agreement with the nonemployee. During the six months ended June 30, 2023 and 2022, 513,000 and 0 common stock shares, respectively, were issued as fully vested, nonforfeitable equity instruments to nonemployees. The agreements with the nonemployees do not include any provisions to claw back the share-based payments in the event of nonperformance by the nonemployees. Subject to applicable federal and state securities laws, the nonemployees can sell the received equity instruments. 120,000 and 100,000 of the common stock shares issued during the six months ended June 30, 2023 were issued to Trevally, LLC and Carmel, Milazzo & Feil LLP, respectively. Before March 31, 2024, Trevally, LLC is expected to provide castanopsermine, a stable starting material to support the manufacture of good manufacturing grade (GMP)-grade celgosivir for clinical studies. Carmel, Milazzo & Feil LLP is expected to provide legal services before March 31, 2024. As of June 30, 2023, the unamortized balance of prepaid assets related to these share-based payments for which the services are expected to be rendered within one year is $1,100,000 ($0 at December 31, 2022), which is reported in Prepaid and Other on the Consolidated Condensed Balance Sheets.
Net Loss per Common Share	Net Loss per Common Share Net Loss per Common Share is computed by dividing net loss by the weighted average number of common shares outstanding during each period. For the purposes of calculating the weighted average number of common shares outstanding for periods prior to the Merger (See Note 6), each of 60P LLC’s outstanding membership units as of June 1, 2022 have been retrospectively adjusted for the equivalent number of common shares issued pursuant to the Merger. As the Company has reported a net loss for all periods presented, diluted net loss per common share is the same as basic net loss per common share for those periods.
Related Parties	Related Parties Parties are considered to be related to the Company if the parties, directly or indirectly, through one or more intermediaries, control, are controlled by, or are under common control with the Company. Related parties also include principal owners of the Company, its management, members of the immediate families of principal owners of the Company and its management and other parties with which the Company may deal with if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.
Subsequent Events	Subsequent Events The Company considers events or transactions that occur after the balance sheet date, but prior to the issuance of the financial statements to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. Subsequent events have been evaluated through August 25, 2023, which is the date the financial statements were issued. See Note 12.
Recently Issued and Adopted Accounting Pronouncements	Recently Issued and Adopted Accounting Pronouncements From time to time, the FASB issues Accounting Standards Updates (“ASU”) to amend the authoritative literature in the ASC. Management believes that those issued to date either (i) provide supplemental guidance, (ii) are technical corrections, (iii) are not applicable to the Company or (iv) are not expected to have a significant impact on these consolidated condensed financial statements. In August 2020, the FASB issued ASU 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”), as part of its overall simplification initiative to reduce costs and complexity of applying accounting standards while maintaining or improving the usefulness of the information provided to users of financial statements. Among other changes, the new guidance removes from U.S. GAAP separation models for convertible debt that require the convertible debt to be separated into a debt and equity component, unless the conversion feature is required to be bifurcated and accounted for as a derivative or the debt is issued at a substantial premium. As a result, after adopting the guidance, entities will no longer separately present such embedded conversion features in equity and will instead account for the convertible debt wholly as debt. The new guidance also requires use of the “if-converted” method when calculating the dilutive impact of convertible debt on earnings per share, which is consistent with the Company’s current accounting treatment under the current guidance. The guidance is effective for financial statements issued for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years, with early adoption permitted, but only at the beginning of the fiscal year. The Company adopted this pronouncement on January 1, 2022; however, the adoption of this standard did not have a material effect on the Company’s consolidated condensed financial statements. In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options. This latter standard provides clarification and reduces diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (such as warrants) that remain equity classified after modification or exchange. This standard is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Issuers should apply the new standard prospectively to modifications or exchanges occurring after the effective date of the new standard. Early adoption is permitted, including adoption in an interim period. If an issuer elects to early adopt the new standard in an interim period, the guidance should be applied as of the beginning of the fiscal year that includes that interim period. The Company’s adoption of this standard in 2022 did not have a material effect on the Company’s consolidated condensed financial statement. In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers, which requires an acquirer in a business combination to recognize and measure contract assets and contract liabilities in accordance with Accounting Standards Codification Topic 606. ASU 2021-08 is effective for fiscal years beginning after December 15, 2022 and early adoption is permitted. The Company’s adoption of ASU 2021-08 did not have an effect on its consolidated condensed financial statements.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2023
Summary of Significant Accounting Policies [Abstract]
Schedule of Liabilities Measured at Fair Value	Liabilities measured at fair value at June 30, 2023 and December 31, 2022 are as follows: June 30, 2023 Level 1 Level 2 Level 3 Total Liabilities: Promissory Notes (including accrued interest), at fair value $ - $ - $ 23,539,996 $ 23,539,996 Derivative Liabilities - - 2,446,091 2,446,091 Total $ - $ - $ 25,986,087 $ 25,986,087 December 31, 2022 Level 1 Level 2 Level 3 Total Liabilities: Derivative Liabilities $ - $ - $ 1,494,200 $ 1,494,200 Total $ - $ - $ 1,494,200 $ 1,494,200
Schedule of Exchange Rates Along with Historical Rates Used in these Financial Statements	Exchange rates along with historical rates used in these financial statements are as follows: Average Exchange Rate Three Months Ended June 30, Six Months Ended June 30, As of Currency 2023 2022 2023 2022 June 30, December 31, 1 AUD = 0.6683 USD 0.7147 USD 0.6761 USD 0.7194 USD 0.6662 USD 0.6805 USD 1 SGD = NA 0.9950 AUD* NA 1.0150 AUD* NA 1.0230 AUD* * Through 4/30/2022 (account closure date)

Inventory (Tables)

Inventory (Tables)	6 Months Ended
	Jun. 30, 2023
Inventory [Abstract]
Schedule of Inventory	Inventory consists of the following major classes: June 30, December 31, Raw Material (API) $ 397,487 $ 397,487 Packaging - 97,486 Finished Goods 301,112 183,943 Clinical Trial Supplies 42,617 63,062 Total Inventory 741,216 741,978 Reserve for Expiring Inventory (275,701 ) (223,400 ) Inventory, net $ 465,515 $ 518,578

Property and Equipment (Tables)

Property and Equipment (Tables)	6 Months Ended
	Jun. 30, 2023
Property and Equipment [Abstract]
Schedule of Property and Equipment	As of June 30, 2023 and December 31, 2022, Property and Equipment consists of: June 30, December 31, Lab Equipment $ 132,911 $ 132,911 Computer Equipment 12,261 12,261 Furniture 3,030 3,030 Property and Equipment, at Cost 148,202 148,202 Accumulated depreciation (140,704 ) (126,902 ) Property and Equipment, Net $ 7,498 $ 21,300

Intangible Assets (Tables)

Intangible Assets (Tables)	6 Months Ended
	Jun. 30, 2023
Intangible Assets [Abstract]
Schedule of Intangible Assets	As of June 30, 2023 and December 31, 2022, Intangible Assets consist of: June 30, December 31, Patents $ 161,032 $ 145,613 Website Development Costs 66,965 27,070 Intangible Assets, at Cost 227,997 172,683 Accumulated Amortization (21,620 ) (8,428 ) Intangible Assets, Net $ 206,377 $ 164,255
Schedule of Estimated Future Amortization Expense for Our Patents and Website Development Costs	The following table summarizes the estimated future amortization expense for our patents and website development costs as of June 30, 2023: Period Patents Website 2023 (remaining six months) $ 1,996 $ 10,161 2024 3,991 20,322 2025 3,991 17,208 2026 3,991 411 Thereafter 31,589 - Total $ 45,558 $ 48,102

Debt (Tables)

Debt (Tables)	6 Months Ended
	Jun. 30, 2023
Debt [Abstract]
Schedule of Promissory Notes	Promissory notes are summarized as follows at June 30, 2023: Knight Therapeutics Note, including amendment Bridge Notes Total Promissory Notes (including accrued interest), at fair value $ 23,539,996 $ - $ - $ 23,539,996 Promissory Notes (including accrued interest) - 1,220,155 1,105,122 2,325,277 Less Current Maturities 23,539,996 - 1,105,122 24,645,118 Long Term Promissory Notes $ - $ 1,220,155 $ - $ 1,220,155 Knight Therapeutics Note, including amendment Bridge Notes Total Promissory Notes (including accrued interest), at fair value $ 16,319,986 1,109,783 535,901 17,965,670 Promissory Notes (including accrued interest) 16,319,986 - 535,901 16,855,887 Less Current Maturities - $ 1,109,783 $ - $ 1,109,783 Long Term Promissory Notes $ 16,319,986 1,109,783 535,901 17,965,670
Schedule of Bridge Notes and Related Party Notes	Bridge Notes and Related Party Notes are summarized as follows at June 30, 2023 and December 31, 2022: 2022 Bridge Related Party 2023 Bridge Issuance date of promissory notes May 2022 May 2022 May 2023 Maturity date of promissory notes 1 1 1 Interest rate 10 % 6 % 10 % Default interest rate 15 % 15 % 15 % Collateral Unsecured Unsecured Unsecured Conversion rate 2 2 2 Face amount of notes $ 888,889 $ 338,889 $ - Less: unamortized debt discount (407,555 ) (155,443 ) - Add: accrued interest on promissory notes 54,567 11,651 - Balance - December 31, 2022 $ 535,901 $ 195,097 $ - Face amount of notes 888,889 338,889 722,222 Less: unamortized debt discount - - (638,100 ) Add: accrued interest on promissory notes 121,480 31,177 10,632 Balance - June 30, 2023 $ 1,010,369 $ 370,066 $ 94,754
Schedule of Reconciliation of the Beginning and Ending Balances for the Convertible Knight Note	A reconciliation of the beginning and ending balances for the Convertible Knight Note, which is measured at fair value on a recurring basis using significant unobservable inputs (Level 3) is as follows for the three and six months ended June 30, 2023: Convertible Knight Note, at fair value Promissory Notes, at fair value at December 31, 2022 $ - Fair value at modification date - January 9, 2023 21,520,650 Fair value - mark to market adjustment (339,052 ) Accrued interest recognized 634,243 Promissory Notes, at fair value at March 31, 2023 21,815,841 Fair value - mark to market adjustment 1,064,849 Accrued interest recognized 659,306 Promissory Notes, at fair value at June 30, 2023 $ 23,539,996
Schedule of the Knight Debenture	The Knight debenture as of June 30, 2023 and December 31, 2022 consisted of the following: June 30, December 31, Original Debenture $ - $ 3,000,000 Unamortized debt discount - (279,061 ) Debenture Prior to Accumulated Interest - 2,720,939 Accumulated Interest - 1,555,670 Debenture $ - $ 4,276,609
Schedule of the Current Future Payment Obligations	The current future payment obligations of the principal are as follows: Period Principal Payments 2023 (remaining six months) $ - 2024 - 2025 - 2026 - 2027 2,804 Thereafter 147,196 Total $ 150,000

Derivative Liabilities (Tables)

Derivative Liabilities (Tables)	6 Months Ended
	Jun. 30, 2023
Derivative Liabilities [Abstract]
Schedule of Derivative Expense	Derivative expense recorded during the three and six months ended June 30, 2022 is summarized as follows: Commitment Date May 24, Fair value of derivative liabilities $ 1,483,888 Less: face amount of debt (979,275 ) Derivative expense $ 504,613 Commitment Date May 8, Fair value of derivative liabilities $ 954,725 Less: face amount of debt (555,000 ) Derivative expense $ 399,725
Schedule of Derivative Liabilities Measured at Fair Value on a Recurring Basis	A reconciliation of the beginning and ending balances for the derivative liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) is as follows at June 30, 2023 and December 31, 2022: Bridge Warrants Convertible Total Derivative liabilities - December 31, 2022 $ 834,352 $ 578,164 $ 81,684 $ 1,494,200 Fair value - mark to market adjustment 4,902 1,689 (1,457 ) 5,134 Derivative liabilities - March 31, 2023 $ 839,254 $ 579,853 $ 80,227 $ 1,499,334 Fair value - commitment date 680,276 274,449 - 954,725 Fair value - mark to market adjustment 8,896 (17,009 ) 145 (7,968 ) Derivative liabilities - June 30, 2023 $ 1,528,426 $ 837,293 $ 80,372 $ 2,446,091 Bridge Warrants Convertible Total Derivative liabilities - December 31, 2021 $ - $ - $ - $ - Fair value - commitment date 823,687 565,007 95,194 1,483,888 Fair value - mark to market adjustment 664 2,932 (2,595 ) 1,001 Derivative liabilities - June 30, 2022 $ 824,351 $ 567,939 $ 92,599 $ 1,484,889
Schedule of Conversion Features in Convertible Promissory Notes	At each subsequent reporting period, we remeasure the fair value of liability-classified bridge shares, warrants and embedded conversion features in convertible promissory notes using the Monte Carlo simulation. Commitment Dates May 2023 May 2022 Stock price $ 5.30 $ 5.00% Volatility 115.1% 99.7% Expected term (in years) - Notes 0.99 1.00-1.03 Expected term (in years) - Warrants 4.99 5.00% Risk-free interest rate 4.80% 2.76% - 2.84 Dividend yield 0% 0% IPO probability (prior to note maturity date) 95% 95% Mark to Market June 30, December 31, Stock price $ 5.30 $ 5.00 Volatility 100.3% - 104.3% 101.9% Expected term (in years) - Notes 0.05 - 0.85 0.39 - 0.41 Expected term (in years) - Warrants 3.89 - 4.85 4.39 Risk-free interest rate 4.16% - 4.33 4.06% Dividend yield 0% 0% IPO probability (prior to note maturity date) 95% 95%

Commitments and Contingencies (

Commitments and Contingencies (Tables)	6 Months Ended
	Jun. 30, 2023
Commitments and Contingencies [Abstract]
Schedule of Future Minimum Lease Payments on a Discounted and Undiscounted Basis	Future minimum lease payments on a discounted and undiscounted basis under the Company’s operating lease are as follows: Undiscounted Cash Flows Discount rate 15.00 % 2023 (remaining six months) $ 27,985 2024 13,992 Thereafter - Total undiscounted minimum future payments 41,977 Imputed interest (2,507 ) Total operating lease payments 39,470 Short-term lease liabilities 39,470 Long-term lease liabilities $ -
Schedule of Other Information Related to our Operating Lease	Other information related to our operating lease is as follows: June 30, Weighted average remaining lease term (in years) 0.75 Weighted average discount rate 15.00 %

Nature of Operations (Details)

Nature of Operations (Details) - Subsequent Event [Member]	Jul. 14, 2023 USD ($) $ / shares shares
Nature of Operations (Details) [Line Items]
Initial public offering shares (in Shares) | shares	1,415,095
Price per unit	$ 5.3
Net proceeds (in Dollars) | $	$ 6,454,300
Common stock of par value	$ 0.0001
Exercise price per share	6.36
Initial Public Offering [Member]
Nature of Operations (Details) [Line Items]
Exercise price per share	$ 6.095

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Summary of Significant Accounting Policies (Details) [Line Items]
Majority owner percentage	87.53%		87.53%
Consolidated owner percentage	100%		100%
Outstanding accounts receivable percentage			24%	76%	30%
Capitalized website development or related costs	$ 6,000		$ 39,895
Development costs corporate website	0		0
Franchise cost			250
Income taxes gross receipts	1,000,000		1,000,000
Income taxes other assets	$ 1,000		1,000
Recognized potential tax penalty			$ 30,000		$ 30,000
Receivables or revenues percentage	10%		10%
Non-related party debt rate			84%		85%
Research and development costs expense	$ 203,872	$ 231,394	$ 327,866	$ 294,451
Share-based payments shares (in Shares)			525,000
Non employees shares (in Shares)	405,000		405,000
Current unamortized deferred cost					$ 279,061
Non-current unamortized deferred cost	$ 1,431,092		1,431,092		0
Equity incentive plan shares			$ 238,601
Share-based payments vested shares (in Shares)			513,000	0
Common stock shares issued (in Shares)	2,378,009		2,378,009
Prepaid and other assets	$ 1,100,000		$ 1,100,000		$ 0
Customer One [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
Concentration percentage			76%		59%
Customer Two [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
Concentration percentage			24%		39%
Revenue [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
Concentration percentage	100%	100%
Receivables or revenues percentage				$ 100	$ 100
Minimum [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
Property and equipment estimated service live	3 years		3 years
Minimum [Member] | Common Stock [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
Common stock shares issued (in Shares)	100,000		100,000
Median [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
Property and equipment estimated service live	5 years		5 years
Maximum [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
Property and equipment estimated service live	7 years		7 years
Maximum [Member] | Common Stock [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
Common stock shares issued (in Shares)	120,000		120,000
Accounts Receivable [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
Outstanding accounts receivable percentage					66%
Concentration percentage			100%		98%
Research and Development Costs [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
Current unamortized deferred cost	$ 3,130,000		$ 3,130,000		$ 0

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details) - Schedule of Liabilities Measured at Fair Value - USD ($)	Jun. 30, 2023	Dec. 31, 2022
Liabilities:
Total	$ 25,986,087	$ 1,494,200
Derivative Liabilities [Member]
Liabilities:
Promissory Notes (including accrued interest), at fair value	23,539,996
Derivative Liabilities		1,494,200
Derivative Liabilities [Member]
Liabilities:
Derivative Liabilities	2,446,091
Level 1 [Member]
Liabilities:
Total
Level 1 [Member] | Derivative Liabilities [Member]
Liabilities:
Promissory Notes (including accrued interest), at fair value
Derivative Liabilities
Level 1 [Member] | Derivative Liabilities [Member]
Liabilities:
Derivative Liabilities
Level 2 [Member]
Liabilities:
Total
Level 2 [Member] | Derivative Liabilities [Member]
Liabilities:
Promissory Notes (including accrued interest), at fair value
Derivative Liabilities
Level 2 [Member] | Derivative Liabilities [Member]
Liabilities:
Derivative Liabilities
Level 3 [Member]
Liabilities:
Total	25,986,087	1,494,200
Level 3 [Member] | Derivative Liabilities [Member]
Liabilities:
Promissory Notes (including accrued interest), at fair value	23,539,996
Derivative Liabilities		$ 1,494,200
Level 3 [Member] | Derivative Liabilities [Member]
Liabilities:
Derivative Liabilities	$ 2,446,091

Summary of Significant Accoun_5

Summary of Significant Accounting Policies (Details) - Schedule of Exchange Rates Along with Historical Rates Used in these Financial Statements	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
AUD [Member]
Intercompany Foreign Currency Balance [Line Items]
Average Exchange Rate			0.6662		0.6805
AUD [Member] | Average Exchange Rate [Member]
Intercompany Foreign Currency Balance [Line Items]
Average Exchange Rate	0.6683	0.7147	0.6761	0.7194
SGD [Member]
Intercompany Foreign Currency Balance [Line Items]
Average Exchange Rate					1.023	[1]
SGD [Member] | Average Exchange Rate [Member]
Intercompany Foreign Currency Balance [Line Items]
Average Exchange Rate		0.995		1.015
[1]Through 4/30/2022 (account closure date)

Inventory (Details) - Schedule

Inventory (Details) - Schedule of Inventory - USD ($)	Jun. 30, 2023	Dec. 31, 2022
Schedule of Inventory [Abstract]
Raw Material (API)	$ 397,487	$ 397,487
Packaging		97,486
Finished Goods	301,112	183,943
Clinical Trial Supplies	42,617	63,062
Total Inventory	741,216	741,978
Reserve for Expiring Inventory	(275,701)	(223,400)
Inventory, net	$ 465,515	$ 518,578

Property and Equipment (Details

Property and Equipment (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Property and Equipment [Abstract]
Depreciation expenses	$ 6,901	$ 6,901	$ 13,802	$ 13,846

Property and Equipment (Detai_2

Property and Equipment (Details) - Schedule of Property and Equipment - USD ($)	Jun. 30, 2023	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
Property and Equipment, at Cost	$ 148,202	$ 148,202
Accumulated depreciation	(140,704)	(126,902)
Property and Equipment, Net	7,498	21,300
Lab Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment, at Cost	132,911	132,911
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment, at Cost	12,261	12,261
Furniture [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment, at Cost	$ 3,030	$ 3,030

Intangible Assets (Details)

Intangible Assets (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Intangible Assets [Abstract]
Amortization expense	$ 6,017	$ 952	$ 13,192	$ 1,962
Capitalized patent expenses	$ 109,241		$ 109,241

Intangible Assets (Details) - S

Intangible Assets (Details) - Schedule of Intangible Assets - USD ($)	Jun. 30, 2023	Dec. 31, 2022
Schedule of Intangible Assets [Abstract]
Patents	$ 161,032	$ 145,613
Website Development Costs	66,965	27,070
Intangible Assets, at Cost	227,997	172,683
Accumulated Amortization	(21,620)	(8,428)
Intangible Assets, Net	$ 206,377	$ 164,255

Intangible Assets (Details) -_2

Intangible Assets (Details) - Schedule of Estimated Future Amortization Expense for Our Patents and Website Development Costs	Jun. 30, 2023 USD ($)
Patents [Member]
Intangible Assets (Details) - Schedule of Estimated Future Amortization Expense for Our Patents and Website Development Costs [Line Items]
2023 (remaining six months)	$ 1,996
2024	3,991
2025	3,991
2026	3,991
Thereafter	31,589
Total	45,558
Website Development Costs [Member]
Intangible Assets (Details) - Schedule of Estimated Future Amortization Expense for Our Patents and Website Development Costs [Line Items]
2023 (remaining six months)	10,161
2024	20,322
2025	17,208
2026	411
Thereafter
Total	$ 48,102

Capitalization and Equity Tra_2

Capitalization and Equity Transactions (Details) - USD ($)		3 Months Ended	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Jan. 31, 2023	Dec. 31, 2022	Jun. 01, 2022
Capitalization and Equity Transactions (Details) [Line Items]
Common stock, shares per value (in Dollars per share)							$ 0.0001
Price per share (in Dollars per share)							$ 5
Common stock, shares issued		2,378,009	2,378,009
Percentage of cancelled shares issued						61%
Percentage of cancelled shares outstanding						61%
Common stock, shares outstanding		2,378,009	2,378,009
Vendors [Member]
Capitalization and Equity Transactions (Details) [Line Items]
Common stock, shares issued		0	1,443,000
60 Degrees Pharmaceuticals, Inc. [Member]
Capitalization and Equity Transactions (Details) [Line Items]
Common stock, shares issued	37,067
Chief Executive Officer [Member]
Capitalization and Equity Transactions (Details) [Line Items]
Price per share (in Dollars per share)	$ 5
Purchase price (in Dollars)	$ 185,335
Tyrone Miller [Member]
Capitalization and Equity Transactions (Details) [Line Items]
Common stock, shares issued				192,101	192,101
Geoffrey S. Dow [Member]
Capitalization and Equity Transactions (Details) [Line Items]
Common stock, shares issued				1,258,899	1,258,899

Deferred Compensation (Details)

Deferred Compensation (Details) - USD ($)			1 Months Ended	12 Months Ended
	Jan. 11, 2023	May 05, 2022	Jun. 17, 2022	Dec. 31, 2022	Jun. 30, 2022	Dec. 31, 2020
Deferred Compensation (Details) [Line Items]
Received consulting services						$ 100,000
Deferred cash compensation		$ 60,000	$ 57,198
Deferred compensation warrants		400,000
Cash component		100,000	38,900
Equity compensation		245,000			$ 155,000
Accrued expenses			$ 12,500
Contingent deferred compensation, percentage			100%
Deferred compensation, common shares			$ 60,000
Deferred compensation, shares issued (in Shares)	65,000			65,000
Deferred compensation, per share (in Dollars per share)				$ 5
Subsequent agreement				$ 325,000
IPO [Member]
Deferred Compensation (Details) [Line Items]
Deferred compensation warrants			$ 10,000,000
Equity compensation		$ 155,000

Debt (Details)

Debt (Details) - USD ($)						1 Months Ended					3 Months Ended			6 Months Ended
	Jan. 09, 2023	Nov. 04, 2022	Jan. 01, 2022	May 14, 2020	Oct. 11, 2017	Dec. 31, 2023	May 31, 2023	May 31, 2022	Mar. 31, 2022	Dec. 27, 2019	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	May 04, 2024	May 11, 2023	Apr. 30, 2023	Apr. 23, 2023	Dec. 31, 2022	May 24, 2022	Apr. 24, 2019
Debt (Details) [Line Items]
Principal amount				$ 150,000					$ 10,770,037
Accrued interest											$ 659,306	$ 634,243
Debenture																						$ 3,000,000
Annual interest rate				3.75%
Debenture interest rate																			9%
Knight Loan amount																				$ 20,596,595
Promissory note issued amount					$ 750,000
Maturity days					60 days				30 days
Interest rate					5%
Interest rate, per annum					10%
Excess fair value discount					$ 120,683
Note and incurred costs					$ 1,767
Amortization discount											24,613		$ 0	$ 48,759	$ 0
Interest expense											31,352		28,401	61,614	55,813
Debt issuance costs																						$ 2,100,000
Amortization of debt discounts														645,336	326,396
Accumulated interest																				1,555,670
Gross proceeds						$ 7,000,000
Initial public offering discount, percentages														15%
Common stock outstanding, percentages														19.90%
Payment of milestones														$ 10,000,000
Regulatory advice value														$ 30,000
Cumulative dividend												6%
Common stock ownership percentage											19.90%			19.90%
Equal royalty pay to lender, percentage			$ 3.5
Extinguishment Amount	$ 839,887
Net increase in fair value														$ 725,797
Additional interest expense														1,293,549
Unamortized original issue discount											$ 0			0						279,061
Committed to monthly payments				$ 731
Interest payments		$ 731
Principal payments											161,366			161,366						163,022
Long-term debt, current maturities														8,772
Long-term liability											152,594			152,594						160,272
Current maturity																				$ 2,750
Payment terms, balloon payment to be paid														32,383
Short term advance, received																	$ 250,000	$ 50,000
Chief Executive Officer [Member]
Debt (Details) [Line Items]
Promissory notes face amount								$ 338,889
Original issue discount rate								10%
Original issue discount								$ 33,888
Debt issuance costs								34,289
Net proceeds								$ 270,711
Notes bear interest								6%
Default interest rate								15%
Face amount, percentage								20%
Pre-money valuation of outstanding shares of common stock								$ 27,000,000
Fully vested warrants exercise price percentage							90%	110%
Knight Therapeutics, Inc. [Member]
Debt (Details) [Line Items]
Principal amount										$ 6,309,823
Accrued interest										4,160,918
Debenture										$ 3,483,851
Annual interest rate																			15%
2022 Bridge Notes [Member]
Debt (Details) [Line Items]
Promissory notes face amount								$ 888,889
Original issue discount rate								10%
Original issue discount								$ 88,889
Debt issuance costs								91,436
Net proceeds								$ 708,564
Notes bear interest								10%
Default interest rate								15%
Face amount, percentage								100%
Pre-money valuation of outstanding shares of common stock																					$ 27,000,000
Fully vested warrants exercise price percentage								110%
2023 Bridge Notes [Member]
Debt (Details) [Line Items]
Promissory notes face amount							$ 722,222
Original issue discount rate							10%
Original issue discount							$ 72,222
Debt issuance costs							95,000
Net proceeds							$ 555,000
Notes bear interest							10%
Default interest rate							15%
Face amount, percentage							100%
Pre-money valuation of outstanding shares of common stock																$ 27,000,000
Fully vested warrants exercise price percentage							110%
Related Party Notes [Member]
Debt (Details) [Line Items]
Amortization of debt discounts														645,336	326,396
Knight Debt Conversion [Member]
Debt (Details) [Line Items]
Accumulated interest									$ 8,096,486
Accumulated capitalized interest costs														100
Debenture [Member]
Debt (Details) [Line Items]
Amortized interest expense											13,696		$ 240,850	13,696	$ 240,850
Geoffrey S. Dow Revocable Trust [Member]
Debt (Details) [Line Items]
Short term advance, received												$ 200,000
Short term advance, received														23,000
Tyrone Miller [Member]
Debt (Details) [Line Items]
Short term advance, received											$ 27,000			$ 27,000

Debt (Details) - Schedule of Pr

Debt (Details) - Schedule of Promissory Notes - USD ($)	Jun. 30, 2023	Dec. 31, 2022
Debt (Details) - Schedule of Promissory Notes [Line Items]
Promissory Notes (including accrued interest), at fair value	$ 23,539,996	$ 17,965,670
Promissory Notes (including accrued interest)	2,325,277	16,855,887
Less Current Maturities	24,645,118	1,109,783
Long Term Promissory Notes	1,220,155	17,965,670
Knight Therapeutics [Member]
Debt (Details) - Schedule of Promissory Notes [Line Items]
Promissory Notes (including accrued interest), at fair value	23,539,996	16,319,986
Promissory Notes (including accrued interest)		16,319,986
Less Current Maturities	23,539,996
Long Term Promissory Notes		16,319,986
Note, Including Amendment [Member]
Debt (Details) - Schedule of Promissory Notes [Line Items]
Promissory Notes (including accrued interest), at fair value		1,109,783
Promissory Notes (including accrued interest)	1,220,155
Less Current Maturities		1,109,783
Long Term Promissory Notes	1,220,155	1,109,783
Bridge Notes [Member]
Debt (Details) - Schedule of Promissory Notes [Line Items]
Promissory Notes (including accrued interest), at fair value		535,901
Promissory Notes (including accrued interest)	1,105,122	535,901
Less Current Maturities	1,105,122
Long Term Promissory Notes		$ 535,901

Debt (Details) - Schedule of Br

Debt (Details) - Schedule of Bridge Notes and Related Party Notes - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
2022 Bridge Notes May 2022 [Member]
Related Party Transaction [Line Items]
Maturity date of promissory notes		1 year
Interest rate		10%
Default interest rate		15%
Collateral		Unsecured
Conversion rate		2
Face amount of notes	$ 888,889	$ 888,889
Less: unamortized debt discount		(407,555)
Add: accrued interest on promissory notes	121,480	54,567
Balance - June 30, 2023	1,010,369
Balance - December 31, 2022		$ 535,901
Related Party Notes May 2022 [Member]
Related Party Transaction [Line Items]
Maturity date of promissory notes		1 year
Interest rate		6%
Default interest rate		15%
Collateral		Unsecured
Conversion rate		2
Face amount of notes	338,889	$ 338,889
Less: unamortized debt discount		(155,443)
Add: accrued interest on promissory notes	31,177	11,651
Balance - June 30, 2023	370,066
Balance - December 31, 2022		$ 195,097
2023 Bridge Notes May 2023 [Member]
Related Party Transaction [Line Items]
Maturity date of promissory notes		1 year
Interest rate		10%
Default interest rate		15%
Collateral		Unsecured
Conversion rate		2
Face amount of notes	722,222
Less: unamortized debt discount	(638,100)
Add: accrued interest on promissory notes	10,632
Balance - June 30, 2023	$ 94,754
Balance - December 31, 2022

Debt (Details) - Schedule of Re

Debt (Details) - Schedule of Reconciliation of the Beginning and Ending Balances for the Convertible Knight Note - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2023	Jan. 09, 2023
Convertible Debt [Abstract]
Promissory Notes, at fair value begining	$ 21,815,841
Fair value at modification date - January 9, 2023				$ 21,520,650
Fair value - mark to market adjustment	1,064,849	$ (339,052)
Accrued interest recognized	659,306	634,243
Promissory Notes, at fair value ending	$ 23,539,996	$ 21,815,841	$ 23,539,996

Debt (Details) - Schedule of th

Debt (Details) - Schedule of the Knight Debenture - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Schedule of the Knight Debenture [Abstract]
Original Debenture		$ 3,000,000
Unamortized debt discount		(279,061)
Debenture Prior to Accumulated Interest		2,720,939
Accumulated Interest		1,555,670
Debenture		$ 4,276,609

Debt (Details) - Schedule of _2

Debt (Details) - Schedule of the Current Future Payment Obligations	Jun. 30, 2023 USD ($)
Schedule of the Current Future Payment Obligations [Abstract]
2023 (remaining six months)
2024
2025
2026
2027	2,804
Thereafter	147,196
Total	$ 150,000

Derivative Liabilities (Details

Derivative Liabilities (Details) - USD ($)	3 Months Ended	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2023	May 24, 2022	May 08, 2022
Derivative Liabilities (Details) [Line Items]
Net change in the fair of derivative liabilities	$ 7,968	$ 2,834
Net change in the fair value of derivative liabilities per share (in Dollars per share)	$ 1,001	$ 1,001
2022 Bridge Notes and warrants [Member]
Derivative Liabilities (Details) [Line Items]
Fair value on the commitment date amount			$ 1,483,888
2022 Bridge Notes and warrants [Member]
Derivative Liabilities (Details) [Line Items]
Net proceeds received	$ 979,275	$ 979,275
2023 Bridge Notes and warrants [Member]
Derivative Liabilities (Details) [Line Items]
Fair value on the commitment date amount				$ 954,725
Net proceeds received	$ 555,000	$ 555,000

Derivative Liabilities (Detai_2

Derivative Liabilities (Details) - Schedule of Derivative Expense - USD ($)	May 08, 2023	May 24, 2022
Schedule of Derivative Expense [Abstract]
Fair value of derivative liabilities	$ 954,725	$ 1,483,888
Less: face amount of debt	(555,000)	(979,275)
Derivative expense	$ 399,725	$ 504,613

Derivative Liabilities (Detai_3

Derivative Liabilities (Details) - Schedule of Derivative Liabilities Measured at Fair Value on a Recurring Basis - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2022
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Derivative liabilities - Opening Balance	$ 1,499,334	$ 1,494,200
Fair value - commitment date	954,725		1,483,888
Fair value - mark to market adjustment	(7,968)	5,134	1,001
Derivative liabilities - Ending Balance	2,446,091	1,499,334	1,484,889
Bridge Shares [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Derivative liabilities - Opening Balance	839,254	834,352
Fair value - commitment date	680,276		823,687
Fair value - mark to market adjustment	8,896	4,902	664
Derivative liabilities - Ending Balance	1,528,426	839,254	824,351
Warrants [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Derivative liabilities - Opening Balance	579,853	578,164
Fair value - commitment date	274,449		565,007
Fair value - mark to market adjustment	(17,009)	1,689	2,932
Derivative liabilities - Ending Balance	837,293	579,853	567,939
Convertible Notes Payable [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Derivative liabilities - Opening Balance	80,227	81,684
Fair value - commitment date			95,194
Fair value - mark to market adjustment	145	(1,457)	(2,595)
Derivative liabilities - Ending Balance	$ 80,372	$ 80,227	$ 92,599

Derivative Liabilities (Detai_4

Derivative Liabilities (Details) - Schedule of Conversion Features in Convertible Promissory Notes - $ / shares	1 Months Ended		6 Months Ended	12 Months Ended
	May 31, 2023	May 31, 2022	Jun. 30, 2023	Dec. 31, 2022
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Stock price (in Dollars per share)	$ 5.3	$ 5	$ 5.3	$ 5
Volatility	115.10%	99.70%		101.90%
Expected term (in years) - Notes	11 months 26 days
Expected term (in years) - Warrants	4 years 11 months 26 days	5 years		4 years 4 months 20 days
Risk-free interest rate	4.80%			4.06%
Dividend yield	0%	0%	0%	0%
IPO probability (prior to note maturity date)	95%	95%	95%	95%
Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Volatility			100.30%
Expected term (in years) - Notes		1 year	18 days	4 months 20 days
Expected term (in years) - Warrants			3 years 10 months 20 days
Risk-free interest rate		2.76%	4.16%
Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Volatility			104.30%
Expected term (in years) - Notes		1 year 10 days	10 months 6 days	4 months 28 days
Expected term (in years) - Warrants			4 years 10 months 6 days
Risk-free interest rate		2.84%	4.33%

Income Taxes (Details)

Income Taxes (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Income Taxes [Abstract]
Provision for income taxes	$ 63	$ 250	$ 126	$ 500

Commitments and Contingencies_2

Commitments and Contingencies (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Commitments and Contingencies (Details) [Line Items]
Operating lease costs	$ 13,859	$ 12,974	$ 27,366	$ 25,947
Common stock value			7,215,000
Contingent payments	$ 43,581		43,581
IPO [Member]
Commitments and Contingencies (Details) [Line Items]
Maximum amount due			305,000
Cheryl Xu [Member] | Board of Directors Chairman [Member]
Commitments and Contingencies (Details) [Line Items]
Cash compensation			11,250
Common stock value			50,000
Restricted stock unit			40,000
Cheryl Xu [Member] | Board of Directors Chairman [Member] | non-qualified option [Member]
Commitments and Contingencies (Details) [Line Items]
Common stock value			50,000
Restricted stock unit			40,000
Paul Field [Member] | Board of Directors Chairman [Member]
Commitments and Contingencies (Details) [Line Items]
Cash compensation			11,250
Common stock value			50,000
Restricted stock unit			40,000
Paul Field [Member] | Board of Directors Chairman [Member] | non-qualified option [Member]
Commitments and Contingencies (Details) [Line Items]
Common stock value			50,000
Restricted stock unit			40,000
Paul Field [Member] | non-audit committee [Member] | Board of Directors Chairman [Member]
Commitments and Contingencies (Details) [Line Items]
Cash compensation			1,250
Charles Allen [Member] | Board of Directors Chairman [Member]
Commitments and Contingencies (Details) [Line Items]
Cash compensation			11,250
Common stock value			50,000
Restricted stock unit			40,000
Charles Allen [Member] | Board of Directors Chairman [Member] | non-qualified option [Member]
Commitments and Contingencies (Details) [Line Items]
Common stock value			50,000
Restricted stock unit			40,000
Charles Allen [Member] | Audit Committee [Member] | Board of Directors Chairman [Member]
Commitments and Contingencies (Details) [Line Items]
Cash compensation			2,000
Stephen Toovey [Member] | Board of Directors Chairman [Member]
Commitments and Contingencies (Details) [Line Items]
Cash compensation			11,250
Common stock value			50,000
Restricted stock unit			40,000
Stephen Toovey [Member] | Board of Directors Chairman [Member] | non-qualified option [Member]
Commitments and Contingencies (Details) [Line Items]
Common stock value			50,000
Restricted stock unit			40,000
Stephen Toovey [Member] | non-audit committee [Member] | Board of Directors Chairman [Member]
Commitments and Contingencies (Details) [Line Items]
Cash compensation			$ 1,250

Commitments and Contingencies_3

Commitments and Contingencies (Details) - Schedule of Future Minimum Lease Payments on a Discounted and Undiscounted Basis	Jun. 30, 2023 USD ($)
Schedule of Future Minimum Lease Payments On A Discounted and Undiscounted Basis [Abstract]
Discount rate	15%
2023 (remaining six months)	$ 27,985
2024	13,992
Thereafter
Total undiscounted minimum future payments	41,977
Imputed interest	(2,507)
Total operating lease payments	39,470
Short-term lease liabilities	39,470
Long-term lease liabilities

Commitments and Contingencies_4

Commitments and Contingencies (Details) - Schedule of Other Information Related to our Operating Lease	Jun. 30, 2023
Schedule of Other Information Related to Our Operating Lease [Abstract]
Weighted average remaining lease term (in years)	9 months
Weighted average discount rate	15%

Subsequent Events (Details)

Subsequent Events (Details)

3 Months Ended

Aug. 09, 2023 USD ($)

Aug. 02, 2023 USD ($) shares

Jul. 25, 2023 shares

Jul. 14, 2023 USD ($) $ / shares $ / item shares

Jul. 12, 2023 $ / shares shares

Jul. 11, 2023 shares

Jun. 30, 2022 USD ($) $ / shares

Mar. 31, 2023 USD ($) shares

Jul. 17, 2023 USD ($) $ / item shares

Jul. 13, 2023 USD ($) $ / item shares

Jun. 30, 2023 USD ($)

Dec. 31, 2022 USD ($)

Jun. 01, 2022 $ / shares

May 31, 2022 USD ($)

May 05, 2022 USD ($)

May 14, 2020

Subsequent Events (Details) [Line Items]

Price per share (in Dollars per share) | $ / shares

$ 5

Deferred equity compensation (in Dollars) | $

$ 155,000

$ 245,000

Converted shares

1,108,337

Cash payments (in Dollars) | $

$ 19,070

$ 264,865

Recognize a gain/loss (in Dollars) | $

$ 9.6

Common shares, outstanding

5,799,535

Interest rate

3.75%

IPO [Member]

Subsequent Events (Details) [Line Items]

Deferred equity compensation (in Dollars) | $

$ 155,000

IPO [Member] | Common Stock [Member]

Subsequent Events (Details) [Line Items]

Shares issued

84,906

Series A Preferred Stock [Member]

Subsequent Events (Details) [Line Items]

Converted shares

80,965

Chief Executive Officer [Member]

Subsequent Events (Details) [Line Items]

Price per share (in Dollars per share) | $ / shares

$ 5

Outstanding principal amount (in Dollars) | $

$ 27,000,000

Consideration amount (in Dollars) | $

$ 185,335

Chief Executive Officer [Member] | Common Stock [Member]

Subsequent Events (Details) [Line Items]

Shares issued on last day of each quarter

15,000

Chief Financial Officer [Member] | Common Stock [Member]

Subsequent Events (Details) [Line Items]

Shares issued on last day of each quarter

12,000

Subsequent Event [Member]

Subsequent Events (Details) [Line Items]

Restricted shares

40,000

Shares issued

1,415,095

Price per share (in Dollars per share) | $ / shares

$ 5.3

Deferred equity compensation (in Dollars) | $

$ 155,000

Shares outstanding percentage

19.90%

Subsequent Event [Member] | Common Stock [Member]

Subsequent Events (Details) [Line Items]

Owned shares

1,153,897

Subsequent Event [Member] | preferred shares [Member]

Subsequent Events (Details) [Line Items]

Owned shares

78,803

Subsequent Event [Member] | Over-Allotment Option [Member]

Subsequent Events (Details) [Line Items]

Underwriters period

45 days

Shares issued

212,265

Price per share (in Dollars per share) | $ / shares

$ 5.28

Subsequent Event [Member] | Tradeable warrants [Member]

Subsequent Events (Details) [Line Items]

Shares issued

60,000

212,265

Price per share (in Dollars per share) | $ / shares

$ 0.01

Exercise amount (in Dollars) | $

$ 381,600

Warrants issued

60,000

Strike price (in Dollars per Item) | $ / item

6.36

Additional shares issued

100,644

Subsequent Event [Member] | Non-tradeable warrants [Member]

Subsequent Events (Details) [Line Items]

Shares issued

212,265

93,000

Price per share (in Dollars per share) | $ / shares

$ 0.01

Exercise amount (in Dollars) | $

$ 566,835

Warrants issued

93,000

Strike price (in Dollars per Item) | $ / item

6.095

Additional shares issued

100,644

Common shares, outstanding

5,753,975

Subsequent Event [Member] | Bridge warrants [Member]

Subsequent Events (Details) [Line Items]

Shares issued

31,447

Exercise amount (in Dollars) | $

$ 183,336

Warrants issued

31,447

Strike price (in Dollars per Item) | $ / item

5.83

Subsequent Event [Member] | IPO [Member]

Subsequent Events (Details) [Line Items]

Net proceeds (in Dollars) | $

$ 6,454,300

Outstanding principal amount (in Dollars) | $

$ 1,950,000

Converted shares

383,908

Cash payments (in Dollars) | $

$ 1,800,000

Recognize a gain/loss (in Dollars) | $

$ 650,000

Subsequent Event [Member] | Knight’s preferred shares [Member]

Subsequent Events (Details) [Line Items]

Shares issued

45,560

Convertible preferred shares

2,162

Subsequent Event [Member] | 60P Australia Pty Ltd [Member] | Minimum [Member]

Subsequent Events (Details) [Line Items]

Ownership percentage

87.53%

Subsequent Event [Member] | 60P Australia Pty Ltd [Member] | Maximum [Member]

Subsequent Events (Details) [Line Items]

Ownership percentage

96.61%

Stephen Toovey [Member] | Subsequent Event [Member]

Subsequent Events (Details) [Line Items]

Restricted shares

10,000

Charles Allen [Member] | Subsequent Event [Member]

Subsequent Events (Details) [Line Items]

Restricted shares

10,000

Paul Field [Member] | Subsequent Event [Member]

Subsequent Events (Details) [Line Items]

Restricted shares

10,000

Cheryl Xu [Member] | Subsequent Event [Member]

Subsequent Events (Details) [Line Items]

Restricted shares

10,000

BioIntelect [Member] | Subsequent Event [Member]

Subsequent Events (Details) [Line Items]

Shares issued

29,245

Xu Yu [Member] | Subsequent Event [Member] | IPO [Member]

Subsequent Events (Details) [Line Items]

Converted shares

214,934

Recognize a gain/loss (in Dollars) | $

$ 90,000

Geoff Dow [Member] | IPO [Member]

Subsequent Events (Details) [Line Items]

Shares issued on last day of each quarter

300,000

Tyrone Miller [Member] | IPO [Member]

Subsequent Events (Details) [Line Items]

Shares issued on last day of each quarter

240,000

60P Australia Pty Ltd [Member] | Subsequent Event [Member]

Subsequent Events (Details) [Line Items]

Shares issued

904,436

Authorized payment (in Dollars) | $

$ 1,000,974

60P, Inc. [Member] | Subsequent Event [Member]

Subsequent Events (Details) [Line Items]

Consideration amount (in Dollars) | $

$ 0

Financing amount (in Dollars) | $

$ 17,000,000

Interest rate

8%